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Abstract 
 
 
The potential of nanobiomedical field for developing a promising therapeutic nano-sized drug 
delivery system is seen to be a great pharmaceutical trend for encapsulation and release of 
various antineoplastic drugs. In this context, the current work is targeting preparation of 
biodegradable chitosan nanoparticles (CSNP) that have been intended for selective and 
sustained release of doxorubicin (DOX) within breast tumor microenvironment. Surface 
modification of these CSNP with Polyethylene glycol (PEG) was performed in order for 
enhancing its blood circulation time without being opsonized or captured by immunogenic 
reticuloendothelial system (RES). PEG has maintained high particles stability profile and 
enhanced its surface positive charge for the sake of intracellular attachment via electrostatic 
attachment with negatively charged tumor cell membrane.  Advanced tumor selectivity has 
been achieved through functionalization of two different types of breast cancer specific 
monoclonal antibodies (mAb); anti-human mammaglobin (Anti-hMAM) and anti-human 
epidermal growth factor (Anti-HER2) in two different separate nano formulations. This 
functionalization has the potential of evading systemic side effects of parenteral free DOX and 
promoting cancerous endocytosis through receptor mediated interaction. In-vitro cytotoxicity 
effects of PEGylated DOX loaded CSNP, free DOX, Anti-HER2 PEGylated DOX loaded 
CSNP and Anti-hMAM PEGylated DOX loaded CSNP were tested against breast cancer cell 
line (MCF7) and normal fibroblast cell line (L929). Notably, Anti-hMAM PEGylated DOX 
loaded CSNP and Anti-HER2 PEGylated DOX loaded CSNP formulations were the most 
cytotoxic against MCF7 cancer cells than L929 normal cells compared to free DOX. 
Confirmatory bright filed images of the two cell lines have exhibited cancerous cellular damage 
after 24 hours exposure time to these nano formulations. Finally, we believe that dose 
dependent system toxicity of freely ingested DOX can be hindered with such targeted nano 
formulated drug delivery system.    
 
 
Scheme 1: Graphical diagram of DOX encapsulation and release within tumor cell  
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Thesis Scope and Objectives: 
 
The current study is an indicative attempt to apply readily available and naturally existent 
polymers; chitosan (CS), in order to enhance the pharmacotherapeutic efficacy of an anti-
cancer drug; Doxorubicin (DOX) and its smart delivery system against breast cancer cell line. 
The main objective here is to design a nano-formulation platform that will be able to travel 
inside the human physiological blood circulatory system. This circulatory journey is oriented 
to be from a certain site of administration till reaching the selected site of action by the aid of 
cell specific ligand(s) known as smart antibodies. This partially invasive drug delivery system 
aims to deliver, localize, and prolong the release of the loaded DOX. Besides, it is an efficient 
system to minimize the undesirable immunogenic uptake of this entire therapeutic platform by 
the effect of mono-nuclear phagocyte system (MPS) that is known, also, as reticuloendothelial 
system (RES). Thereby, facilitating the accumulation of effective doses of DOX within the 
tumor environment without harming the other non-cancerous organs. Thus, minimizing its 
severe side effects like heart failure, bone marrow suppression, mucositis and alopecia (1).  
 
The referred nanoparticles conjugated system will be based on a biodegradable and 
biocompatible polymeric chitosan nanoparticles (CSNP) which will be functionalized with 
Polyethylene Glycol (PEG), DOX and biological marker(s) over the different chapters and 
activities of this study. In activity 1, the CSNP will be prepared within a bottom-up approach 
using ionotropic gelation method (2). The resultant nanoparticles will be characterized using 
different characterization analysis in order to confirm the consistency of their crosslinking, 
size, shape, distribution, morphology and surface charge. Various characterization techniques 
have been exploited for this purpose such as Dynamic Light Scattering (DLS), Scanning 
Electron Microscopy (SEM), Transmission Electron Microscopy (TEM), X-Ray Diffraction 
(XRD), Ultraviolet-Visible spectrophotometry (UV-VIS) and Infrared spectroscopy using 
Fourier Transform Infrared Spectroscopy (FTIR). In Activity 2, the prepared CSNPs have been 
loaded with a polymeric Polyethylene Glycol (PEG). The main purpose behind adding this 
polymer has been to ensure a prolonged and extended circulation of the nanoparticles till 
reaching the breast tumor area without being uptake by RES. These PEGylated CSNP have 
been characterized, also, using the same characterization analysis as activity 1. (3)  
 3 
 
Encapsulation of DOX inside the PEGylated CSNP has been done as the third activity. This 
step has been done with very minute concentrations of DOX. These minute concentrations 
have been tested in terms of encapsulation efficiency (EE%), loading capacity (LC%) and cell 
cytotoxicity. The dye compound 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromidefor colorimetric assay (MTT assay) has been an indicative test of the most effective 
DOX concentration that can kill the highest percentage of MCF-7 breast tumor cells (3). The 
concentration of choice has been tested for the drug release behavior in order to monitor and 
expect its behavior inside the tumor microenvironment. Besides cell cytotoxicity test, this 
activity has been characterized also with FTIR, TEM, Zeta-sizer, Zeta potential and UV-Vis 
spectroscopy. These characterization analyses have confirmed the successful encapsulation 
and stability of DOX inside the PEGylated CSNP. Achieving such dose reduction with 
maintaining good stability of this nano-formula in normal saline pH is an outstanding step for 
obtaining efficient delivery process of highly effective doses of DOX. Therefore, the 
integration of such multidisciplinary nanosystem into pharmaceutical DOX drug delivery 
process has empowered its activity against breast tumor cells.     
 
 
 
Scheme 2: Full schematic diagram of different work activities in this study 
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1.1. Cancer  
 
For many decades, cancer has been recognized as one of the top unresolved threatening health 
problems that represents the second leading cause of death worldwide according to some 
contemporary reports by World Health Organization (WHO). Typically, cancer can start within 
any organ in the body at any time for many identified and unidentified etiologies as shown in 
Figure (1.1) (4). The main problem with cancer is the fast cellular growth of a group of mutated 
cells that are known as tumor cells. Basically, Cancer starts with one normal healthy cell that 
develops a damage or unexpected change in its Deoxyribonucleic Acid (DNA) molecule. This 
change, which may be inherited or developed by many factors such as radiation, oxidative 
stress, infection, smoking and hormonal disturbances can cause gene mutation and rather 
interfere with the normal cell division instructions. Therefore, it turns from a normal cell to a 
cancerous cell that grows out of control. Tumor is developed when this cancer cell continues 
to grow and divide.  
 
Figure 1.1: Initiation of cancerous tumor by the action of genetic alteration that results from various 
environmental factors. (5)  
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Tumor cells don’t have any specific physiological function in the human body, and they can 
easily avoid the immune system. Besides, they ignore the physiological signals that aim to 
control or stop cell division. The tumor grows and gets bigger by the flood of oxygen and 
different types of nutrients using blood supply through cancerous angiogenesis formation as 
illustrated in Figure (1.2) (6).  
 
 
Figure 1.2: The angiogenesis pathway of a cancerous tumor with overexperession of VEGF glycoprotein results 
in initiation of new microblood vessels that feed and carry nutrients and oxygen to tumor area so that, the tumor 
cells can divide and grow easily (7) 
 
The increased numbers of cancer diseased cases worldwide are tremendously growing every 
day, the mortality rate at 2018 has been 9.6 million deaths (5). In Aisa, the highest mortality 
rate, the estimated number of death cases has been more than 5 million. While the remaining 
amount of death cases has been localized in different areas worldwide including Europe, 
Africa, Oceania and North America as shown in Figure (1.3) (B). On the other hand, the 
estimated economic expenses that has been accompanied with cancer treatment in US is about 
$1,16 Trillion per year. Besides, more than 300,000 new cancer cases among the age of 0-19 
years are being annually diagnosed. Therefore, it has been proposed by some WHO guidelines 
that patient awareness and early screening of a tumor can improve the treatment access (8).   
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(A)                                                                           (B) 
 
Figure 1.3: (A) Total cancer prevalence rate in 2018 including various types of cancer with various 
physiological sites in human body, with total estimated number of 18,078,957 cancer patients. (B) estimated rate 
of death cases because of cancer all ages and all types in by the end of 2018 that reached around 9.6 million 
worldwide (8) 
   
1.2. Breast cancer 
 
Breast cancer is the highest comon cancer type within female population, and it has been ranked 
worldwide as one of the top leading causes of high death rates among the same demographic 
population section. Being one of the top international public health issues over the century, 
breast cancer has a direct influence on different dimensions of human lives including 
physiological, psychological, mental and social aspects. Meanwhile, it has an incidence rate of 
more than 2.1 million new cases every year as shown in Figure (1.3 A). In 2018, the mortality 
rates of breast cancer have been 627,000 deaths as shown in Figure (1.4 A). 
 
 
(A)                                                                   (B)  
Figure 1.4: (A) Different types of cancer with variable death rates including breast cancer (6.6%) death rate in 
2018, (B) the incidence rate of Breast cancer in different world zones for 2018 (8) 
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Anatomical picture of a female’s breast tissue is composed of a group of lobes that are 
estimated as 10-20 lobes (9). Each of these lobes is made up of many smaller lobules which 
function as glands that produce and carry the breast milk. These lobules are connected together 
by ducts that act as a passing canal for milk drainage from the lobules to the nipples. The second 
part of breast tissue is called stroma which is a supporting tissue that integrates the surrounding 
connective tissue and fatty tissue. Typically, breast cancer originates at the cells of either the 
lobules (lobular carcinoma) or ducts (ductal carcinoma), or any type of these supporting tissues 
as shown in Figure (1.5). 
 
 
Figure 1.5: Schematic representation of breast tissue anatomy (10) 
 
 
1.3. Types of breast cancer: 
 
1.3.1. Preinvasive breast cancer: 
 
It is a less frequently dominated cancer type which originates only and locally inside either the 
milk ducts or milk lobules. It doesn’t spread outside these specific two sites. They can be 
considered as the early stage or precancerous states of breast cancer. Typically, this type of 
cancer can easily respond to early treatment. It represents around 25% of all known types and 
subtypes of breast cancer. For instance, in United Kingdome, around 7400 women get such 
preinvasive breast cancer every year which may originate in breast duct known as ductal 
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carcinoma in situ (DCIS), or in breast lobule known as lobular carcinoma in situ (LCIS) (11). 
A Full detailed description of the different types of breast cancer is illustrated in Figure (1.16).   
 
1.3.1.1. Ductal Carcinoma in Situ (DCIS): 
 
Ductal carcinoma can be diagnosed as cancerous cells that grow locally inside the walls of 
ducts and don’t invade the external surrounding breast tissues. Approximately, all women with 
such type of tumor can be cured easily and the early detection of such type is, also, another 
helpful factor for efficient treatment. Because such tumor type is confined locally within the 
ductal tissue only, DCIS is also known as intraductal or non-invasive cancer. It is not a life-
threatening subtype, but in rare cases it can develop a more sever invasive type. Usually, 
women develop such breast cancer subtype after the age of 48 yrs (12). DCIS can be 
subcategorized into three types; low grade, intermediate grade and high grade. The last two 
types can be screened as a thick mass accompanied with some nipple discharge.  
 
 
Figure 1.6: Schematic illustration of ductal carcinoma in situ (13)  
 
 
1.3.1.2. Lobular Carcinoma in Situ (LCIS):  
 
This type of cancer tumor is another confined and localized tumor. The cells grow exclusively 
inside the lining lobules only without harming the adjacent walls and tissues or cells. Although 
it is physiologically confined, it can however be diagnosed hardly using such advanced 
screening as mammograms. Some studies have proposed that such type may not be considered 
as a real type of breast cancer, but they consider it as a marker for future tumor.  It is detected 
as a change in the cellular structure in a biopsied tissue. It differs from DCIS as if it was left 
without treatment, it won’t proceed to such aggressive invasive subtype (13, 14). 
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Figure 1.7: Schematic illustration of lobular carcinoma in situ (LCIS) (13) 
 
1.3.2. Invasive breast cancer:  
 
This is a non-confined breast cancer tumor in which the cells are growing out of control and 
spread outside the ductal and lobular tissues. The tumor grows outside the confined areas as 
shown in figure (1.8) (A). It represents around 75% of breast cancer tumor types and has been 
estimated that the US is developing 180,000 invasive breast cancer cases every year (14). The 
majority of this number is diagnosed with invasive ductal carcinoma. It can affect women 
population randomly at any stage of their ages. Besides, invasive breast cancer can affect men 
population as well.  
 
(A)                                                 (B) 
Figure 1.8: The difference between invasive tumor (A), and non- invasive or in-situ tumor (B) (15) 
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1.3.2.1. Invasive ductal carcinoma:  
 
This type of aggressive breast cancer represents around > 80% of the invasive carcinoma. It 
initiates mainly in the ductal lining and spread out within the nearby breast tissues as shown in 
figure (1.9) (A). Such tumors use physiological blood stream and lymphatic pathways in order 
to move outside the breast tissue which is known as metastasis. Its main diagnosis starts with 
screening of a lump or mass that the physician can identify. The use of X-ray supported 
Mammogram is highly considered (16). 
 
1.3.2.2. Invasive Lobular carcinoma:  
 
It is the second most common type of aggressive breast tumors that accounts for around 15% 
of the breast tumor cases. It spreads out of the lobular tissue through the fatty and connective 
tissues as shown in figure (1.9) (B). Usually, the lobular carcinoma in situ (LCIS) is the main 
precursor of this type. Its metastasis is mainly located within the abdominal area such as colon, 
uterus, and ovary. 
 
Figure 1.9: Illustrative figure shows the difference between invasive ductal carcinoma and invasive lobular 
carcinoma (17)  
1.3.3. Molecular subtypes (Receptor mediated breast cancer):  
 
Clinically, breast cancer tumors have been categorized according to the presence of certain 
hormonal known receptors and the status of these receptors. Histologically, there are three 
types of cellular receptors that are attached to breast tumor cells; estrogen receptors (ER), 
progesterone receptors (PR) and human epidermal growth factor receptor 2(HER2) as shown 
in Figure (1.10) (18). 
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Figure 1.10: Three basic types of receptors within breast tumor cell (19) 
 
1.3.3.1.  Estrogen receptor mediated breast cancer: 
 
Around 65 % of breast cancer tumors are estrogen receptors positive (ER+) meaning that these 
tumor cells have estrogen receptors in the outer surface of their cellular membranes.  
Physiologically, estrogen receptors are functioning as stabilizers for the effect of the 
endogenous estrogen and, in some cases, responding to other therapeutic agents (20). Only 15-
20 % are considered to be estrogen receptors negative (ER-). This type of breast cancer is 
riskier than ER+. Patients with ER+ tumors are typically treated with hormonal therapy, 
immunotherapy and/or chemotherapy. They respond well to such types of therapies as shown 
in Figure (1.11).  
 
Figure 1.11: The effect of anti-estrogenic drug Tamoxifen up on placebo and tamoxifen treated breast cancer 
patients. (21) 
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1.3.3.2.  Progesterone receptor mediated breast cancer: 
 
Progesterone (PR) is one of the endogenous steroidal hormones that is involved in different 
physiological processes such as embryogenesis, pregnancy and menstruation cycles. It has 
been stated that progesterone is involved, also, in breast cancer tumor progress. 
Physiologically, PR is functioning as an activator for rapid activation of protein kinase that is 
involved in some modification processes of proteins. Additionally, it acts as a mediator for 
signals transduction pathways within the breast tissues.  Therefore, it has been found that the 
presence of such PR receptors can play a role with the development, growth and even the 
treatment of the breast cancer. Likewise, in ER mediated tumors, some patients have been 
found to efficiently respond to hormonal treatment. Those are patients with PR+, respond to 
anti-progesterone drugs as shown in Figure (1.12) While others with PR- don’t respond well 
to hormonal therapy and they respond, majorly, to chemotherapy and immunotherapy (22). 
 
 
 
Figure 1.12: The anti-progesterone action with a breast cell mediated progesterone (23)  
 
1.3.3.3. human epidermal growth factor receptor 2(HER2) breast cancer:  
 
HER2 is an over expressed oncogene that is naturally existent on the external surface of normal 
breast and tumor breast cells. Normally, in a healthy woman, HER2 is responsible for cell 
growth, division and self-repair.  Basically, HER2 has been discovered during early 1980s, and 
it has been stated to be one of the key factors that participate in the development of breast tumor 
within 15 – 20 % of the total patient population. This oncogene is responsible for encoding 
various types of fundamental proteins that are responsible for maintaining persistent tumors 
 14 
 
growth. The overexpression of HER2 gene in breast cancer patients is originated by its cellular 
mutation related over amplification, and this results in initiation of too many HER2 receptors 
as shown in figure 1.13. Theses receptors are responsible for uncontrolled growth and division 
of tumor cells (24).     
 
 
 
Figure 1.13: Difference between HER2 positive and HER2 negative breast tumor cell (25) 
 
 HER2 (+ve) tumor cells provide their own tumor growth through a proliferative, angiogenic 
and cell progressive pathway as shown in figure (1.14). This pathway is enzymatic based 
network that is supported with many different signals that develop a cascade manner which 
ends up with uncontrolled growth of the tumor (26).    
 
 
Figure 1.14: HER2 signaling pathway with a cascade manner that ultimately target the final breast 
tumorigenesis (26) 
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1.3.4. Triple Negative Breast Cancer (TNBC): 
 
This is a major heterogeneous challenging aggressive type of breast carcinoma that occurs in 
young women. TNBC is mainly characterized by the absence of the most important three types 
of receptors that feed the tumor cells; ER, PR and HER2 receptors. This represents a distinct 
challenge in front of so many trials for controlling the growth of such type. The distinct 
aggressive nature associated with this type is related to the lack of targeted therapy besides its 
critical pathological nature. It has been estimated that TNBC represent around 20% of all 
worldwide invasive breast cancer patients as shown in figure (1.15) (A) (27). 
 
(A)                                                                          (B) 
 
Figure 1.15:  The Incidence rates of molecular types of breast cancer (A) and subtypes of TNBC (B) (28) 
 
TNBC has many different molecular subtypes as shown in Figure (1.15) (B) and Table (1.1); 
Luminal A, Luminal B, Immunomodulatory (IM), mesenchymal stem-like (MSL), 
mesenchymal (M), basal like 1 and 2 (BL1, BL2), luminal androgen receptors (LAR) and 
normal tumors (29). The molecular profile for TNBC entails that the majority of infected 
patients are basal like category. This category is characterized by overexpression of CK5 and 
CK14 genes, which are used immunohistochemically for diagnosis of solid breast carcinomas 
like intraductal papilloma with usual ductal hyperplasia (IPUDH).  
 
Table1.1: Various subcategories of TNBC with their relative genetic characteristic behaviors (30) 
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Figure 1.16: Pathogenesis of breast cancer including both molecular and histologic types (31) 
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1.4. Stages of breast cancer:  
 
Many worldwide health and treatment organizations that are concerned with the global public 
health have proposed and classified different stages of breast cancer according to many factors. 
For instance, size of the tumor, hormonal receptors overexpression, type of the tumor, how 
deep the tumor is within the healthy unaffected breast tissues, metastatic tendency to nearby 
organs and spreading to the nearby lymph nodes. However, the most often applied system for 
staging has been the American Joint Committee on Cancer (AJCC) (32). This system is called 
TNM system that stands for (Tumor Node Metastasis), and it classifies breast cancer according 
to two main sub-classifications; clinical and pathological (Table 1.2)  
 
Table 1.2: TNM grading system for different stages of breast cancer (33) 
 
TNM  Description  Stage  patients (%) 
Tumor (T) 
T0  Tumor is not formed  0 NA 
T1 Tumor < 2 cm 1 6.8% 
T2 Tumor (2 cm – 5 cm) 2 19.7% 
T3 Tumor ≥ 5 cm 3 28.4% 
T4 Tumor of any size 4 45.4% 
Lymph node (N) 
N0 No tumor in lymph nodes  0 20.9% 
N1 Non movable tumor 1 24.9% 
N2 Movable Tumor 2 31.7% 
N3 Tumor in 4 – 10 lymph 
nodes  
3 22.5% 
N4 NA 4 NA 
Metastasis (M) 
M0 No metastasis  0,1,2,3 83% 
M1 Distant metastasis  4 17% 
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o Stage 0:  
This is the earliest stage of breast cancer that is characterized by a noninvasive nature of 
the tumor, and sometimes called in-situ carcinoma. The cancerous and non-cancerous cells 
are separated from each other and there is no evidence of any cancerous invasion. The 
prognosis and treatment possibilities in this stage are high, since there are separate 
boundaries between the growing cancerous cells and healthy cells.  DCIS can be considered 
as example of such stage. 
 
o Stage 1: 
This is the secondary stage that provides a descriptive picture of invasive carcinoma. 
Sometimes microscopic examination of such invasion is a rigid evidence of this clinical 
grade. Through this examination, physicians can define the general size of the tumor and 
the involvement of the nearby lymph nodes. Some studies differentiate between stage 1A 
and 1B (33). In stage 1A, the tumor’s size can reach 2 cm while keeping the adjacent lymph 
nodes unaffected. While in stage 1B, the tumor’s size may reach 0.2 mm while the adjacent 
lymph nodes are affected and involved in the tumor growth.  
 
o Stage 2:  
The size of the tumor in this stage is < 5 cm and having the adjacent lymph nodes affected 
with the tumor. Likewise, stage 1, this stage is classified into two sub classes; 2A which 
has a tumor growing in the axillary or sentinel lymph nodes, while the breast tissue has no 
tumor. On the other hand, in 2B subclass, the tumor is large and reaches to 5 cm, though it 
doesn’t reach the adjacent lymph nodes.  
 
o Stage 3:  
This is one of the advanced stages of breast tumor in which the axillary lymph nodes are 
highly involved with having a large tumor size of 5 cm. It can be sub-classified into three 
stages; A, B and C. Breast tumor of stage 3A, tumor is found to be between 5 – 9 axillary 
lymph nodes. In stage 3B, Tumor is found in 9 axillary or sentinel lymph nodes. This type 
is called inflammatory breast cancer since it has a swelling of the affected skin area. In 
stage 3C, tumor is found in more than 10 lymph nodes.  
o Stage 4: 
This stage of breast cancer is known as metastasis, and characterized by the spread of tumor 
cells to the nearby organs including distant organs such as liver, bone, colon and brain and 
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distant lymph nodes. Physicians may call this tumor type ‘De Novo” and it has some 
possibility at this stage that the tumor is a recurrence of a previous breast cancer.  
Table 1.3: Five years survival rates of different stages of breast cancer (34) 
Stage Description  5 years 
survival rate  
Stages 0 and 1 Primary diagnosed cancer (high curability rate) 90 % 
Stage 2 Early stage breast tumor (intermediate curability rate) 70% 
Stage 3 Advanced carcinoma (augmented therapy is required) 48% 
Stage 4 Late stage metastatic breast carcinoma (very low 
curability rate) 
20% 
 
1.5. Breast cancer current therapy: 
 
1.5.1. Surgery 
 
Surgery is the main traditional management strategy that has a prominent role in evading breast 
tumor. This strategy is prioritized over many other treatment techniques for those patients 
whose tumors are localized and did not metastasize to further areas of the nearby body organs 
(35). Additionally, surgery is highly considered, also, for such patients who are at late complex 
stages of breast cancer. In these stages, the removal of axillary or sentinel lymph nodes and 
other breast lesions are the main targets for performing a surgery as showed in Figure (1.17).  
 
                                                                           
(A)                                                   (B) 
Figure 1.17: (A) Removal of sentinel lymph nodes with blue colored drainage, (B) removal of axillary lymph 
nodes (35) 
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o Mastectomy:  
 
This is one of the well-known breast surgeries that entails the removal of the whole breast 
tissue including the outer skin tissue and axillary lymph nodes. According to many studies, 
this is one of the options that are offered for early stages patients such as primary stages; 
1,2 and 3 and non-invasive DCIS and LCIS patients. Some preventive procedures, also, 
may recommend such surgery for patients who are believed to be at high risk of having 
later breast carcinoma (36).  
 
o Lumpectomy: 
 
It is a partial surgical procedure that is less inclusive than mastectomy. It entails the removal 
of a benign part of the breast. In other words, lumpectomy is a partial mastectomy that is 
highly recommended for patents whose malignant tumors are surrounded by healthy non-
cancerous tissues including lymph nodes. Notably, most surgeons and patients as well 
recommend lumpectomy than mastectomy owing to their high concern with losing breast-
based asexuality (37).  
 
1.5.2. Radiotherapy: 
 
It is one of the highly considered treatment methodologies that proved its effectiveness in 
evading and control many breasts malignant tumors’ growth. Radiotherapy could be a 
completely curative treatment for some breast cancer cases. A combination therapy that 
combines radiotherapy with many other therapeutic techniques may enhance the survival 
benefits in many breast carcinomas. Wang et al has recently conducted a rigid conclusion of 
minimizing the breast tumor recurrence rates of 50% within 10 years survivals when radiation 
therapy has been combined with breast tumor surgery (38). Moreover, the death rate, also, has 
been decreased by 20% for 15 years.   
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Figure 1.18: Different types of radiation therapy based on the affected area and the conducted surgery (39)  
 
Clinically, many randomized and retrospective studies have reviewed the acute and chronic 
toxicity profiles associated with adjuvant radiotherapy on breast cancer patients. The size of 
the breast is a one indicative factor that may enhance or diminish the radiotherapy toxicity as 
shown in figure (1.19).  
 
 
 
Figure 1.19: Different Toxicity and severity rates with different breast sized patients (40)  
 
 
Harsolia et al. has demonstrated a strong relationship between the breast edema, dermatitis and 
chronic hyperpigmentation relative to the intensity of the breast size. Besides, Shah et al. has 
concluded the same sever rates of these aforementioned adverse effects. Moist desquamation, 
subcutaneous fibrosis and breast shrinkage have been reported by Pignol et al. for 5 years 
simple radiation therapy as shown in Figure (1.20) (41).   
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(A)                                                                               (B)  
 
Figure 1.20: (A) Radiotherapy related breast skin fibrosis, (B) Moist desquamation of a radiotherapy affected 
breast (42)  
 
 
1.5.3. Hormonal therapy:  
 
In premenopausal patients, the prevention of estrogen action is achieved through two major 
techniques; ovarian ablation or the use of therapeutic estrogen analogues such as Luteinizing 
hormone releasing hormone (LHRH) like goserelin (Zoladex©). In the same context, selective 
estrogen receptor modulators (SERM), like tamoxifen and raloxifene, is frequently used as 
adjuvant treatment for ovarian cancer and breast cancer. It has been reported by a collaborative 
study that tamoxifen has shown a significant reduction of the tumor recurrence rate by 74%, it 
could also minimize the death rate by 26% (43). Another adjuvant hormonal treatment that has 
attracted some oncological interest is selective estrogen receptor degrader (SERD) like 
fulvestrant. This type of therapy is used to damage or degrade the estrogen receptors. It is often 
applied for post-menopausal women and sometimes it can be combined with goserelin in order 
for augmenting their antagonizing effect against breast tumor.     
  
Postmenopausal breast cancer patients, who represents quiet higher rates than premenopausal 
patients, have 80% of their breast tumors ER+. Physiologically, estrogen in postmenopausal 
women is produced in minute quantities through some organs such as breast tissues, liver and 
adrenal glands. That is because their ovaries are no longer producing sufficient estrogen. It has 
been shown according to Czick et al. that some hormonal treatment, such as tamoxifen and 
aromatase inhibitors (AIs), can effectively stop the conversion of androgens hormones to 
estrogens through inhibition of the aromatase enzyme as shown in Figure (1.21) (44).  
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Figure 1.21: Inhibition of estrogen action through Hormonal therapy (45) 
 
 
1.5.4. Chemotherapy:  
 
 
Anthracyclines (a subcategory of chemotherapy) has been reported by many studies as the most 
potent class of chemotherapeutics that can interfere with such enzymatic associated cell growth 
(46). The initiation of redox reactions by anthracyclines has a powerful role on generating 
reactive oxygen species (ROS). These ROS causes oxidative stress and cancerous cell death. 
In the same context, anthracyclines interfere with topoisomerase II enzyme whom inhibition 
arrest the cancerous cell growth. Therefore, the use of chemotherapy is highly recommended 
in sever cancer types, such as TNBC and HER2+, including stages 3and 4. These late stages 
have characteristic inclusion of metastasis and lymphatic carcinomas with independence of 
size of the tumor, patient age and nodal status (47).  
 
On the other hand, having various therapeutic alternatives is always recommended owing the 
wide adverse effects that can be clinically decisive in shifting between different treatment 
options. Chemotherapy has been listed by WHO as one of the top recommended treatment 
plans of breast carcinoma. Chemotherapy has been reported as a source of generating ROS, 
this caused a programed cardiotoxicity for patients who receive various chemotherapeutic 
agents. It’s been for many years with a great conflict of the imbalance between the risks and 
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befits of using chemotherapy and the evoked cardiotoxicity. Besides, the significant adverse 
effect of hair loss associated with chemotherapy has been discussed with many retrospective 
studies (48). The other mild to severe adverse reactions of chemotherapy have been reported, 
also, by many clinical studies are listed in Table (1.4). They include nausea, vomiting, fever, 
abdominal pain, photosensitivity, constipation, mucositis, azoospermia, co-enzyme Q10 
deficiency, alopecia, injection site reaction, rash, pruritis and infection (49). 
 
Table 1.4: Various adverse effects of using chemotherapy after one-month treatment (50) 
 
 
1.5.4.1. Doxorubicin: 
It is one of the chemotherapeutic anthracycline type of antibiotics that is obtained from a 
specific bacterium species called Streptomyces Peucetius as shown in figure (1.22). DOX has 
been used for the curing of solid based cancerous tumors in all ages; children and adults. It has 
been used, also, for effective treatment of soft tissues tumors such as ovarian cancer, bladder 
cancer, neuroblastoma, thyroid cancer, soft tissue sarcoma and breast cancer. It has been 
approved by FDA at 1974 as one of the safe medicines for cancer treatment. Additionally, it 
has been managed to be one of the tops WHO lists of the most effective drugs against cancer 
by many health practitioners (52).    
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(A)                                                                       (B) 
 
Figure 1.22: (A) Chemical formula of DOX, (B) DOX bacterial strain of Streptomyces Peucetius (51) 
 
1.5.4.2.  Mechanism of action of DOX: 
 
DOX have been elucidated with its intense ability to confine and limit the cancerous tumor’s 
growth with various modes of actions.  
o First, generating stressful ROSs. DOX and anthracyclines, in general, contain 
hydroxyquinone which is chelating structure for elements like iron. By the aid of some 
mitochondrial mediators such as NADH dehydrogenase and cytochrome P450 
reductase, iron-DOX complex enhances the conversion of electrons from glutathione 
to oxygen and its derivatives. This results in accumulation of ROS and production of 
free radicals as shown in Figure (1.23) (53). 
 
o Hydroxyl radicals, single oxygen, superoxide ions and hydrogen peroxide are 
accumulated inside the cell and can’t be detoxified. This causes DNA damage and 
gradually trigger cancerous cell apoptosis. The cell membrane lipids are exposed to 
peroxidation, and this causes rabid destruction of cell membrane. Loss of energy and 
activated lipid metabolism are other findings for such the oxidative stresses (54).  
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Figure 1.23: Programmed cell death of cancerous cell with DOX (anthracycline) (54)  
 
o Second, it interferes with the actions of Topoisomerase-II (TOP II) enzyme which is 
fundamental enzyme for the completion of DNA structural stabilization. Therefore, 
DOX arrests the relegation of the small DNA breaks and, thereby, block the cellular 
growth. Then, finally, it enhances gradual apoptosis.  
 
o Third, DOX has an intercalation activity between the double helical base pairs of the 
cancerous DNA. Therefore, it interferes with the synthesis of DNA and RNA, and this 
in turn inhibit cancerous cell division (55)  
 
o Finally, it has been reported by Chapner et al. that DOX interferes with the function of 
vascular nitric oxide synthase, thus disrupt the vascular tone of the angiogenic blood 
vessels that transfer blood and nutrients to the tumor area (56). It is effective, also, to 
kill the disseminated cancerous cells that are resistant to hormonal therapy or are 
metastatic. Various generic pharmaceutical products are listed in table (1.5). 
 
Table 1.5: Examples of generic pharmaceutical market products (57, 58) 
 
Generic drug Conc. Administration company Year 
Adriamycin® 2mg/mL Intravenous  West-Ward Pharmaceutical 
Corps 
1996 
DOX HCL® 2mg/mL Intravenous  Fresenius Kabi 2000 
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DOX HCL® 2mg/mL Intravenous  Pfizer Inc.  2011 
DOX HCL® 2mg/mL Intravenous  Sun Pharmaceuticals  2012 
DOX HCL® 2mg/mL Intravenous  Actavis Pharma 2014 
DOX HCL® 2mg/mL Intravenous  Athenex Pharmaceutical 
Division  
2017 
DOX HCL® 2mg/mL Intravenous  Dr. Reddy's Laboratories Inc 
 
2018 
 
1.5.4.2.1. Limitations of non-targeted DOX:  
 
The main hindrance to DOX clinical anticancerous application has been its non-selective 
pharmacological activity against healthy and tumor cells. This poor selectivity generates dose 
dependent toxicity and severe side effects within normal cells. One of the widely conducted 
sever toxicity is its known intense cardiotoxicity. The second considerable hindrance is the 
elevated levels of DOX cellular resistance. These two main reasons besides many other adverse 
drug reactions are the top restricting clinical effects that cause treatment failure (59). 
 
 It has been reported that 11% of patients receiving DOX are experiencing these adverse 
reactions within the first few days of treatment. Furthermore, Oikonomou et al. has reported 
that cardiac arrhythmias have been manifested in 26% of DOX receiving breast cancer patients 
during the first 5 years of treatment. Another clinical study, Luu et al., has revealed a 50% 
mortality within the first year of DOX administration being manifested with acute 
cardiotoxicity and congestive heart failure (CHF) (60). Some other drug-drug interactions are 
summarized in table (1.6). 
 
Another drawback for the conventional use of DOX is the elevated drug resistance levels owing 
to the multiple frequent dosing system. The severity and clinical grade of the tumor are the two 
main reasons for such multiple doses. This elevated resistance is associated with many reasons; 
first, the overexpression of multiple drug resistance -1 gene (MDR1) and multi drug resistance 
protein (MRP). Second, impaired DNA repairing, which improve the tumor cell apoptotic 
resistance. Third, mutation and enzymatic degradations of Topoisomerase II, which change the 
expression level of topoisomerase II. Finally, alteration of the cellular membrane fatty acid 
composition that deteriorate some cellular repair mechanisms (61).    
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Table 1.6: Drug-drug interaction with resulted adverse reactions of doxorubicin vs some frequently administered types of drugs for a cancer patient 
  
Co-administered drug Drug-drug interaction Mechanism Solution  Ref. 
N-nitrosouria 
(streptozocine)  
Increased DOX toxicity and 
bone marrow suppression  
Prolong the half-life elimination 
of DOX  
Decreased doses of DOX  (62) 
Digoxin  Decreased blood serum level of 
digoxin 
Reduced intestinal absorption of 
digoxin 
Changing the does regimen of 
digoxin 
(63) 
Quinolone antibiotics  I. Increased DOX toxicity  
II. Decreased antibacterial 
activity of quinolones  
I. Inhibited cytochrome P450 
3A4 and cytochrome P450 
1A2; responsible for dox 
metabolism 
II. Decreased systemic 
absorption of quinolones  
Caution and dose monitoring  (64, 65) 
Cyclophosphamide  Added cardiotoxicity  Reduced metabolism of DOX Avoided  (66) 
Barbiturates 
(phenobarbital) 
Decreased DOX efficacy  increased plasma clearance of 
DOX 
One of them should be stopped 
based on a risk-benefit ratio 
evaluation. 
(67) 
Cyclosporine  Increased DOX related 
cardiotoxixity with a high 
serum level of more than 50% 
Cyclosporines interfere with P-
glycoprotein and reduce DOX 
metabolism by reducing CYT 
P450 enzyme.  
Caution with regular checking  (68) 
Antiviral (stavudine and 
zidovudine) 
Minimize the antiviral activity  Decreased intracellular 
activation  
Avoided  (69) 
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1.6. Targeted drug delivery:  
In the same sense and over the past decade, researchers have combined the use of 
pharmaceutical sciences to nanoscience as a trial for achieving highly effective targeting 
treatment. This combination has brought different optimized formulas for the targeted delivery 
of wide variety of components such as proteins, antibodies, narrow therapeutic indices drugs, 
poorly water-soluble drugs, organic based drugs and polymeric drugs. Besides, the implication 
of nanoscience has provided as new controlled release drug delivery systems which is 
therapeutically outstanding and cost effective as well. Nanoparticles could effectively prove its 
durability and efficacy as a successful nano-based platform for the synthesis of promising 
anticancer treatment. The scientific concept behind this system is shown in Figure (1.24). The 
nanoparticles act as a protective carrier that carries an entrapped drug. This drug, whether water 
soluble or insoluble, is carried either inside it or upon the particle’s surface. The loaded amount 
of drug is released in a controllable manner over certain time. The nanoparticle is marked with 
certain biological marker in order for targeted and specific delivery of the entrapped drug. This 
biological marker can be antibody, protein or DNA molecule (70).  
 
Figure 1.24: Simplified illustration of a nano-based drug delivery system (70) 
1.7. Nanotechnology:  
 
Nanotechnology has been shown to the light of medicinal and bio-medicinal applications for 
many years. It could open the door in front of fabrication of various nanosized material 
formulations that have been used within many various applications. Various Nano formulated 
shaped material have been reported in many studies including dendrimers, polymeric 
nanoparticles, quantum dots, core-shell nanoparticles and carbon nanotubes (figure 1.25). All 
these nano- formulations have been fabricated with high control over their chemical, electrical, 
physical and biological safety applications (71). Generally, a material within the nanoscale 
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behave as if it is completely new material in terms of optical, magnetic, chemical and physical 
performance, especially when its intended application is size dependent.  
 
Figure 1.25: Nanometer scale with relative sizes of various biological objects (72) 
 
Synthesis of nanoparticles can be engineered for performing various surface and core 
modifications within the nanoparticles. Two main approaches for manufacturing nanoparticles; 
bottom-up and top-down approaches. During both methodologies, nanoparticles can be 
conjugated with different types of ligands including functional chemical groups, biological 
molecules, permeation enhancers, targeting moieties, magnetic dyes or surface cross-linkers. 
Furthermore, the beauty of nanotechnology, in general, is that there is a good control over the 
resulted final geometrical shape of the nanostructure. For instance, nano-rod, nano-spheres, 
nano-cubes, nanofibers and nanowires as shown in Figure (1.26).    
 
 
 (A) (B) (C) 
Figure 1.26: TEM images of various shapes of nanostructures; (A) nanoparticles, (B) nanocubes and (C) 
nanorods (73)  
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Biologically, nanotechnology develop another spectacular manipulation of some serious 
specifications such as stability in different pH, surface charges, and drug release. These 
properties are extremely critical whenever the intended application has been biological or 
therapeutic. Therefore, there are five available routes of administration for any nano-based 
structures as illustrated in Figure (1.27). That is because there are many variables included to 
affect the intended nanoparticles such as immune response, enhanced permeability retention 
(EPR), lymphatic drainage and the pH of the diseased or affected organ area. All these factors 
can strengthen or weaken the pharmacological action of the loaded drug. Breast cancer has 
some characteristic pathological features for which nanotechnology can be a considerable 
solution for such problematic issues.   
 
Figure 1.27: Five routes of administration for nano based drug delivery systems 
 
1.8.  Nanotechnology enhanced pH manipulation: 
 
First, breast tumor environment is generally acidic in nature. Some reports have reported that 
the microenvironment of the breast tumor is ranging between pH (6.5 – 6.9). While the normal 
blood stream pH value is neutral to slightly alkaline; ranging between pH=7.2 – 7.5 (75). The 
reason for this pH difference is known as Warburg effect (76). This phenomenon differentiates 
between healthy and cancerous cells. Normally, mitochondrial phosphorylation is the main 
source of energy for the cell to obtain ATP. While cancerous cell uses metabolic glycolysis to 
obtain its energy. This glycolysis ends up with accumulated levels of pyruvate and lactate. This 
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occurs within anerobic conditions that are attained by the action of tumor acidosis which 
minimize the amount of oxygen that is required for keeping the organ area healthy as shown in 
Figure (1.28).  
 
 
 
 
Figure 1.28: Schematic representation of mitochondrial phosphorylation and glycolysis (78) 
 
Furthermore, DOX has been reported by Fukamachi et al. as one of the chemotherapeutic drugs 
whose therapeutic efficacy is not changed between the acidic and alkaline environments. 
Indeed, it rather showed more cytotoxic efficacy within highly acidic and larger tumor sizes 
than smaller less acidic. These results are agreed, also, with Hiroshi et al. (79). In other words, 
the larger the tumor size, the higher therapeutic efficacy that DOX has Figure (1.29).    
 
 
Figure 1.29: pH dependency scale relative to cancerous tumor size (79) 
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1.9. Nanotechnology enhanced surface charge manipulation:  
 
Second, and on the same context, cancerous cell membrane of the tumor cell is negatively 
charged. That is because the accumulated lactate anions tend to remove the positive ions and 
leaving the cancerous cell membrane with negative charges. The poor blood perfusion is a 
supporting factor for this cellular reaction. Therefore, the fabricated nanoparticles that are 
intended to work in such environment should have certain specifications. They are preferred to 
have a net positive charge upon their surfaces, so that an electrostatic interaction can maximize 
the internalization rate of the positively charged nanoparticles. Besides, it has been developed 
by Osaka et al. that the accumulation rates of nanoparticles would be greater when electrostatic 
interaction between the nanoparticles and cancer cell membrane takes place. This would 
provide better drug diffusion with a controlled release behavior as shown in Figure (1.30) (80). 
 
Figure 1.30: Electrostatic interaction between nanoparticles (+ve) and cancerous cell wall (-ve) has developed 
instant drug release (80)   
1.10.  Nanotechnology enhanced biomarker attachment: 
 
One of the main effective advantages that entails the great role of nanotechnology in 
therapeutics is the ability of attaching targeting moieties to the surfaces of the drug carriers. 
These moieties are acting as a guiding monitor that direct the nanoparticle or nanocarrier from 
the site of drug introduction to the site of action which is breast area. Attaching such targeting 
moiety has been a great next step for a new era in designing effective drug delivery systems. 
Nanotechnology enables many researchers to conduct various types of biomarker attached 
nano-formulations that are directed for the treatment of various diseases. Some examples for 
various nano-based drug delivery systems are shown in Table (1.7). The guidance of such nano 
formulations is going to be routed in one of two targeting pathways; active and passive 
targeting Figure (1.31) (81).  
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1.10.1. Passive targeting:  
 
Passive targeting entails the accumulation of the injected nano formulations within the tumor 
tissue with enhanced extravasation out of the tumor. Theses targeted nano formulations could 
efficiently penetrate the tumor through some factors such as their small nano-size, leaky 
vasculature, disorganized permeable blood vessels. The main reasons for such leaky nature of 
these blood vessels are hypoxia, inflammation and lack of nutrients due to high metabolic rate. 
This leakage tendency is referred as enhance permeability retention (EPR). Within these leaky 
permeable vessels, larger pores are formulated and allow transfer of particles with size up to 
400 nm (82). Some studies have assumed a much broader range of these pores’ sizes of (380 – 
780) nm (53).  
1.10.2. Active targeting: 
 
Active targeting is highly efficient ligand-receptor interaction that promote a targeted and 
precise drug release within the tumor environment. This interaction is taken place between the 
overexpressed surface epitopes of the tumor cell and the attached ligand biomarkers. It is more 
efficient than passive targeting (83). The entrapped drug is guaranteed to be released and 
diffuse inside the cell with active targeting. Once the ligand receptor conjugation takes place, 
plasma membrane close so that an internalization endosome is formulated.   
 
 
 
Figure 1.31: Schematic illustration that differentiate between active (A) and passive targeting (B) (84)
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 Table 1.7:  Example of different nanostructured drug delivery formulas that are assisted with various biological targeting moieties. 
Nanostructure Monitored 
disease  
Targeting 
moiety 
Target  Entrapped drug Mode of 
action 
Ref. 
 
Multiwalled carbon 
nanotube 
Colon cancer  Hyaloronic acid  CD44 receptors that are over expressed on 
colon tumor cells  
Gemcitabine 
(chemotherapeutic 
anticancer) 
(Gemzar ®) 
Intracellular (85) 
 
Liposomes  
Non-small 
cell lung 
tumor  
GE11 peptide  Epidermal growth factor receptors 
(EGFRs) 
DOX 
(chemotherapeutic 
anticancer) 
Intracellular (86) 
 
Dendrimers  
Ovarian 
cancer  
Primary antibody 
(mAbK1) 
 
Mesothelin, a glycosyl-
phosphatidyl inositol (GPI) protein 
 
Paclitaxel 
(chemotherapeutic 
anticancer)  
Intracellular (87) 
 
Polymeric micelles  
Pancreatic 
cancer  
anti-tissue factor 
(TF) antibody 
(clone 1894   
 
Pancreatic overexpressed tissue factors 
antigen receptors. 
Oxaliplatin (platinum 
derived 
chemotherapy) 
(Eloxatin ®) 
 
Intracellular (88) 
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1.11.  Nanotechnology enhanced prolonged biological circulation:   
 
One of the critical factors that affect the therapeutic efficacy of the intended Nano formulated 
drug is its rapid biological clearance. During this biological journey, this nano-formulation 
encounter many biological defending mechanisms that slow down their migration and, in turns, 
speed up their elimination through lymphatic drainage. Immunologic reticuloendothelial 
system (RES) and mononuclear phagocyte system (MPS) are phagocytic systems that is 
majorly existent in the liver (89). This system is capable of capturing the nanocarrier and 
deteriorate its action through immunological phagocytosis.  
 
Generally, in order for a drug carrier to be therapeutically effective, it must have some criteria 
available upon its biological ingestion. It must be (1) non captured and escape from the RES 
and MPS, (2) of high stability profile along over its biological journey till reaching the tumor 
area, (3) circulate freely within the systemic blood circulation without being encountered by 
various immunological responses and (4) accumulate within the tumor area so that a 
therapeutic concentration of the drug is released (90). For this purpose, some polymers are 
being suggested to be used so that we ensure high versatility and solubility of the nanocarrier. 
Hao et al. have suggested the use of polyethylene glycol (PEG) and poly (lactic co-glycolic 
acid) (PLGA) as hydrophobic co polymers in order for solubilization of water insoluble drugs. 
Owing to the biological performance, this study has reported the preference of coated 
nanoparticles than uncoated nanoparticles. Another study, Nadeem et al., has developed the 
use of poly-vinyl alcohol (PVA) as a coating material for iron oxide nanoparticles-based drug 
delivery system (91).  
 
1.12. Chitosan as a nanoparticle platform: 
    
CS has been therapeutically used as a polymer based nano drug platform (s) for the delivery of 
various drug types that are intended for the treatment of many diseases like breast cancer. 
Different nano-formulations of CS have been suggested to be used for such biomedical 
application such as CS nanoparticles, nano fibers, nanoliposomes and nanogels (92). CS 
possesses a prolonged circulation behavior and low immune clearance rates. Besies, it has what 
is called shielding effect against RES system that retard its detection (93). Furthermore, CS has 
the ability to efficiently penetrate the tight junction of the epithelial membranes, therefore, it 
has an improved permeation through this junction.    
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Chitosan nanoparticles (CSNP) have been used as a successful drug carrier of many anticancer 
agents for breast cancer therapy. Many studies have conducted a better antitumor activity for 
CSNP loaded with various anticancer drugs compared to these free unloaded drugs. Table (1.8) 
is showing the potential of some CSNP to be used as efficient drug delivery systems in breast 
cancer therapy. CSNP can be synthesized with many applicable preparation techniques such as 
ionotropic gelation, emulsification-crosslinking, co-precipitation, reverse micellization, 
microemulsion, desolation, solvent evaporation and coacervation (94).  
 
 
Figure 1.32: preparation of CS by deacetylation of chitin (95) 
 
Ionotropic gelation is a simple and direct preparation technique that allow synthesis of 
crosslinked CSNP within aqueous conditions. It represents an electrostatic bridging between 
positively charged CS (through amine NH2 group) and negatively charged polyanionic polymer 
such as tripolyphosphate (TPP), genipen and glutraldehyde. The result of such bridging is 
formation of a complex gel like structure that represent crosslinked CSNP. Therefore, 
ionotropic gelation is more preferred than other techniques. Besides, it doesn’t require the use 
of extensive preparation conditions such as high-tech procedures and the burdens of using 
organic solvents (96). 
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 Table 1.8: Some CSNP formulations used for breast cancer drug delivery  
Nano- 
formulations  
Coating 
agent  
Particles size  Synthesis  Drug Target 
cancer  
Route of 
administration 
Mechanism of 
action   
Ref 
CSNP + 
PLGA 
PLGA  (90 – 105) nm  Ionotropic 
gelation 
DOX  Breast cancer  Topical 
(implant) 
Passive targeting 
(EPR, 
extracellular) 
(97) 
CSNP Uncoated  (100 – 150) nm solvent 
evaporation  
Tamoxifen  Breast cancer  Systemic 
(intravenous) 
pH responsive 
(extracellular)  
(98) 
CSNP 
(micellar 
form) 
 α-tocopherol 
succinate 
 
81.4 ± 10.5 nm  
 
coupling 
reaction 
 
Paclitaxel and 
Docetaxel 
Breast cancer  Systemic 
(intravenous) 
Charge affinity 
(intracellular)  
(99) 
CSNP (core-
shell) 
PEG  (34 – 48) nm Copolymer 
grafting  
Anti-HER2 drug 
(trastuzumab) + 
DOX 
Breast cancer  Systemic 
(intravenous)  
Targeting ligand  (100) 
CSNP Thiolation  (200 – 700) nm  Self-assembly DOX Breast cancer  Systemic 
(intravenous) 
Targeting ligand 
enhanced 
antibody-antigen 
interaction 
(101) 
CSNP  Uncoated  473 ± 41 nm 
 
Ionotropic 
gelation  
DOX General 
cancer 
therapy  
Systemic 
(intravenous) 
EPR  (102) 
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TPP has been shown to be more biologically safe than other polyanionic gelation polymers as a 
cross-linker for synthesizing CSNP. It is one of the considerable factors that influence many 
specifications of the resulted nanoparticulate system such as size average, surface charge, and 
particles distribution (see appendix SI). Moreover, the mixing technique of TPP into acidic CS 
aqueous solution affect these parameters as well. For instance, dropwise addition, one-shot 
addition and dilution techniques are three different mixing procedures that lead to variation of size, 
distribution and potential of the resulted CSNP (103). 
 
 
 
Figure 1.33: chemical formula of Sodium tripolyphosphate (104) 
 
1.13. Polyethylene glycol (PEG):  
 
PEG is a synthetic hydrophilic based polymer that has been used in numerous pharmacotherapeutic 
applications such as wound dressing and drug delivery. It has unique chemical properties such as 
biocompatibility, solubility, neutrality, non-irritating and odorless. It is composed of a linear chain 
of polyether with hydrophilic terminal groups of OHs as shown in figure (1.34). This hydroxyl 
group is responsible for its hydrophilicity, and it acts as electron donor. This electronic donation 
is responsible for many chemical characteristics of PEG including its good compatibility with 
organic solvents through weak hydrogen bonding interaction. This allow rapid release of the 
entrapped pharmaceutical drug. PEG has low melting temperature and fast solidification rate; 
therefore, it can be used preparation of chemical and organic dispersions (105). It has been 
approved as biodegradable polymer with non-immunogenicity and nonantigenicity effect for safe 
biological applications by FDA (106). For these reasons, it is widely used as encapsulating or 
coating agents with various nanoparticles-based drug delivery systems  
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Figure 1.34: Chemical structure of polyethylene glycol (107) 
 
 
1.14. Anti-Mammaglobin antibody (Anti-hMAM):  
 
MAM has been demonstrated as a protein-based biomarker antigen that is overexpressed on the 
cellular surfaces of all breast tumor cancer types. Many studies have encountered the analysis of 
MAM as breast cancer biomarker. The results recommend the independent use of MAM as a 
diagnostic and therapeutic biomarker. These promising results have put MAM as one of the 
targeting ligands that entails an antigen-antibody interaction upon the membrane surface of breast 
tumor cells (108).  
 
 In this context, in breast tumor cells, the membrane associated MAM interaction can play a very 
important role in designing an actively targeting drug delivery system for minimizing the growth 
of such tumor tissue. By conjugating MAM to a nanoparticulate carrier that entrap antineoplastic 
drug will promote its therapeutic activity within the acidic based microenvironment of breast tumor 
area (109). This open the door in front of nanoscience and biopharmaceutical science for 
improving new methodologies of breast cancer curing. However, the number of reports that have 
been conducted on the use of this biomarker for active targeted breast cancer drug delivery systems 
are yet low. The potential of anticipated frequent application of such biomarker is still growing. 
Lian et al. has conducted a nano-based drug delivery of doxorubicin to the breast tumor area. Anti-
hMAM has been used as a specific targeting ligand for specific targeting of breast tumor tissue 
(110). The results of this study came promising with efficient specific membrane targeting and 
functional drug carrying signaling system.     
 
MAM has been discovered first in 1994 by Watson-Fleming within breast tissue cells. They could 
identify MAM-A and MAM-B. The overexpression of MAM-A receptors is restricted to breast 
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cancer patients only, while MAM-B is related to various tumor organs such as ovary, thyroid, 
uterus and breast (110, 111). Leygue et al. has experimentally concluded the diagnostic capability 
of MAM-A for diagnosis of breast cancer in a clinical study. The study has applied reverse 
transcriptase polymerase chain reaction (RT-PCR) to test the over-expression of the MAM-A 
coding RNA in 20 breast tumor affected females with advanced lymph nodes tumors. The results 
have confirmed its over expression with a recommendation of using MAM-A as a diagnostic target 
in breast cancer.    
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Chapter 2 
 
Materials & Methods 
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2.1 Materials: 
 
The materials used for the current experimental work were purchased from different local and 
international sources. CS polymer of low molecular weight (LMW) with 89.9% deacetylation 
degree and 65 cp viscosity was purchased from Priemex ehf, Chitoclear®, Iceland. Polyethylene 
glycol (PEG), acetic acid 100%, potassium bromide (KBr) (FTIR grade, ≥99% trace metals basis), 
and Dulbecco’s modified Eagle’s medium (DMEM), were purchased from Sigma Aldrich, Germany. 
DEMEM reagent was supplemented with 4500 mg/L glucose, L-glutamine, sodium pyruvate, 
sodium bicarbonate, 10% FBS, and 5% penicillin/streptomycin. Anhydrous sodium tri-poly 
phosphate (TPP) (technical grade 85%) was purchased from Sigma Aldrich®, Missouri, USA. 
Doxorubicin hydrochloride (molecular weight of 579.96 g/mol) was purchased from Sigma 
Aldrich®, Switzerland (Suisse). Anti HER2 and anti Mammoglobin antibodies (originated from 
rabbit source) were purchased from Sigma Aldrich®, Steinheim, Germany.  Phosphate buffered 
saline (PBS) was purchased from BioWhittaker® Reagents, Lonza, Walkersville, USA. For 
cleaning and sterilization purposes, acetone and Ethanol 99.9% were purchased from Medical Pure 
Life®, Europe and Alamia®. Egypt, respectively. 1-Ethyle-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) was purchased from Sigma Aldrich®, Switzerland (Suisse).  MTT reagent, 3-
[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide and dimethyl sulfoxide (DMSO), 
were purchased from Serva Electrophoresis, Heidelberg, Germany. Fetal bovine serum (FBS), 
Trypsin EDTA, Penicillin/Streptomycin, were obtained from Lonza, Switzerland. CO2 incubator 
(Heracell incubator, Thermo Scientific, USA). Most of the other aforementioned chemicals and 
materials were stored in a well-controlled storage conditions including ventilation, humidity and 
temperature. 
 
 
2.2. Preparation of Chitosan nanoparticles (CSNPs): 
 
Chitosan nanoparticles (CSNPs) have been fabricated using Ionotropic gelation technique as 
referred by many different studies with some modifications including various processing factors 
as described in the supporting information appendix; part 1 (SI.1) (112). Ionotropic gelation 
method is a soft and straightforward technique in which CS NPs can simply be formulated via 
electrostatic interaction between acidic phase and alkaline phase. In other words, whitish clouds 
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of nanoparticles were spontaneously prepared upon addition of TPP (alkaline phase) as a 
negatively charged cross-linking agent, to the positively charged poly-cationic chitosan solutions 
(acidic phase) as shown in Figure (2.1). Various concentrations of acidic chitosan solutions 
(0.05%, 0.25%, 0.5% and 1%) were used against various concentrations of TPP aqueous solution 
(0.1%, 0.4%, 0.5% and 0.7%) as illustrated in the appendix (SI.2.1). The chitosan acidic solution 
and TPP solution were filtered first with syringe filters of 0.4 and 0.2 µm pores sized filters 
respectively before the crosslinking addition (113).  
 
 
Figure 2.1: Cross-linked CS with TPP (113) 
 
 
TPP was dropped to chitosan acidic solution in a dropwise manner within a moderate stirring 
speed. The mixture was left for proper mixing while keeping the applied mixing technique, time 
and rate within acceptable ranges Figure (2.2). The stirring time was adjusted to 30 min with low 
stirring speed of 250 rpm at room temperature. By comparing various mixing techniques such as 
hand stirring, magnetic stirring, homogenization or sonication, the magnetic stirring was 
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efficiently applied over other stated methods. It is simple and possesses a strong effect on reducing 
the sizes of CS NPs (114).  
 
 
Figure 2.2: General scheme for preparation of CS NPs  
 
In order for ensuring high stability of the formulated CS NPs, some factors such as polymers’ 
concentrations, pH, molecular weights of chitosan, stirring time and stirring speed were studied in 
a more detailed manner as shown in the appendix (SI.2). All these factors have a direct influence 
on size, particle charge and stability of the resulted nano-system. Each factor was experimented 
and studied independently, and the resulted recommended parameters that were applied for our 
current study are listed in Table (2.1).  
 
Table 2.1: Optimum conditions for the applied factors in preparation of CS NPs  
 
 
 
 
 
 
 
 
 
 
 
 
Preparation Factors Applied parameters 
Molecular weight of chitosan  Low molecular weight chitosan, DA 89.9% 
Concentration of chitosan  1% Acetic acid aqueous solution (1%) 
Concentration of TPP 0.4% Aqueous solution  
pH 5  
Stirring time  30 minutes  
Stirring speed  250 RPM 
Temperature  Ambient room temperature 
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The resulted samples of the synthesized CS NPs were representing a mélange of various 
concentrations of chitosan and TPP (see the appendix, SI.2 and Table S2). After successful 
formation of whitish clouds of nanoparticles, the mixtures were centrifuged for 30 min at 10,000 
rpm. These specific centrifugation parameters were enough to separate the formulated 
nanoparticles (115). The resulted biphasic system, after centrifugation, was divided into two parts 
as shown in the appendix (SI.1.3 and table 1). The first part was the supernatant, which was 
discarded since it contained the unreacted polymers and acetic acid residues. The second part 
separated nanoparticles pellet was re-suspended in fresh distilled water to be washed from any 
excess un-reacted chitosan and TPP. The washing process was done twice at 10 min centrifuging 
time at 5000 rpm, and this part was divided according to the sampling process for further 
characterization experiments (116).   
 
2.3. Stability of CS NPs:  
 
Stability of the formulated CS NPs as a candidate for the following anticancer tests was crucial 
step. For investigating the stability of the surface of the resulted nanoparticles, their mean particles 
diameter size, surface zeta potential and poly distribution index (PDI) were analyzed by using 
Malvern Zeta sizer (NANO ZS, Malvern, UK) (see appendix SI.3, and Table 6) (117).  An 
indicative stability profile was developed, and the samples were incubated in fresh distilled water 
with pH of 7.2 for three weeks at room temperature, and the required data of the size, distribution 
and surface zeta potential were collected over this stated period. 
 
 2.4. Coating of CS NPs with Polyethylene Glycol (PEG): 
 
CS NPs showed different stability profiles with different conditions, resulted in some variations 
for successful delivery of the entrapped material inside these nanoparticles. Some specifications 
within the physical or chemical structure of the resulted CS NPs could be modified or tailored so 
that they could fit within the desired intended application. For instance, the poor water solubility 
of sole chitosan in water revealed some drawbacks with some chitosan-based drug delivery 
systems of some hydrophilic drugs (118). Increasing hydrophilicity of CS NPs and enhancing the 
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stability of an entrapped hydrophilic drug are two examples of specific properties that could be, 
fortunately, modified with a hydrophilic polymer like polyethylene glycol (PEG) (119). The 
modification adjusted by grafting this copolymer to the basic structure of CS NPs was reported in 
the literature as successful platform of maintaining high nanoparticles’ stability. This process is 
known as “PEGylation” and the resulted PEGylated CS NPs are called “stealth” (120).  
 
Table 2.2: Sample variations relative to the polymeric concentrations of PEG while keeping TPP and Cs 
concentrations fixed  
 
Sample Cs (%) TPP (%) PEG (%) 
1 0.4 1 5 10 
1 √ √ √   
2 √ √  √  
3 √ √   √ 
 
 
PEGylated CS NPs were prepared following Calvo et al. with some modifications (121, 122). This 
aims to provide high particles stability profile and enhance application durability on the final 
selected PEG concentration.  Three different aqueous solutions of PEG (1%, 5% and 10%) were 
prepared as shown in table 2.2 by using a simple stirring speed around 500 rpm for 30 min at room 
temperature. All other preparation parameters were kept constant, so that the optimal functioning 
conditions can provide a sole explanation of the physical and chemical properties of the resulted 
nanoparticles. After dissolving PEG in distilled water, we could identify three different PEG 
concentrations whose viscosities varied according to the weighted amount of PEG powder. The 
dissolution of PEG didn’t require addition of any excipients like acetic acid or any additives. That’s 
because it is readily water-soluble polymer and has an FDA (Food and Drug Administration) 
approval for safe pharmaceutical and food applications (123).    
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Figure 2.3: General scheme for preparation of PEGylated CS NPs  
 
The three aforementioned prepared PEG concentrations were added drop-wisely to the chitosan 
acidic solution (CS 1%). Then, the three mixtures were left for mixing for 30 min with stirring 
speed of 250 rpm. This provided three homogenous mixtures of both polymers; chitosan and PEG. 
The PEGylated CS NPs were formulated upon drop wise addition of TPP solution to chitosan 
acidic solutions containing the previously stated PEG concentrations as shown in Figure (2.3) and 
(2.4). Ionotropic gelation process started upon cross-linking of PEGylated chitosan solutions with 
the polyanion TPP. This process took place immediately, and the three mixtures were left on the 
magnetic stirrers for 30 min at low stirring speed of 250 rpm at the ambient temperature. Then, the 
PEGylated CS NPs were centrifuged and separated from the excess unreacted chitosan, TPP, PEG 
and acetic acid residues. The separation was performed by centrifuging at 10,000 rpm for 30 min 
at 24°C using HERMILE Labotechnik 36 HK centrifuge (Germany) (see Appendix SI.4.4). The 
resulted pellet of PEGylated CS NPs was later divided into three parts like those non-PEGylated 
CS NPs that were discussed in the appendix (SI. 1.3 and table 1) (124).   
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Figure 2.4: Chemical scheme for preparation of PEGylated cross-linked CS NPs (112)  
 
Some vital parameters were identified such as size, external morphology, surface zeta potential 
and PDI of the resulted PEGylated CS NPs. The effect of various concentrations of PEG on these 
parameters was analyzed. It was confirmed that change in PEG concentration could affect such 
parameters of these nanoparticles. This was confirmed before by some previously published 
reports (125). The effects of PEGylation process on the external positive amino groups and hence 
the stability of PEGylated CSNPs were studied also in accordance with another previously 
published study (112).      
 
2.5. Encapsulation of Doxorubicin (DOX) within CS NPs:  
 
The capability of PEGylated CS NPs to effectively entrap anticancer DOX drug was evaluated in 
this phase. After successful preparation of stable, biologically durable and biocompatible 
PEGylated CS NPs, we have studied different protocols that were intended for prosperous 
encapsulation of a hydrophilic drug inside the core of PEGylated CS NPs’ structure (127). These 
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protocols have identified the use of different drugs including DOX. PEGylated CS NPs were the 
same nanostructured matrix that was used as the platform to deliver these drugs. This study is 
mainly dependent on the efficient use and modification of DOX’s pharmacological action. Many 
reasons that were related to the physical and chemical properties of the intended drugs were 
analyzed for the specific use of DOX over other anticancer drugs as will be discussed in more 
details in the next chapter (128). 
 
Integrating DOX within such nan-formulation was expected to provide many effective 
pharmacological and non-pharmacological indications over sole non encapsulated DOX. 
Furthermore, PEGylated CS NPs were expected to entrap such hydrophilic DOX and travel inside 
the bloodstream without leaking the loaded drug or being captured by the immunologic responding 
reticuloendothelial system (129). All preparation parameters were fixed in order to investigate the 
effect of different concentrations of DOX (table 2.3) on the encapsulation efficiency. Additionally, 
the preparation procedure was performed in light protected environment due to the photo-
degradation nature of DOX (130).  
 
Table 2.3: Sample variation relative to DOX concentrations while keeping the polymeric concentrations for Cs, 
TPP and PEG fixed. 
 
Sample Cs (%) TPP (%) PEG (%) DOX (µg/ml) 
1 0.4 5 1.25 2.5 5 10 
1 √ √ √ √    
2 √ √ √  √   
3 √ √ √   √  
4 √ √ √    √ 
 
After dissolving PEG in acidic chitosan solution, it was left to be mixed for 30 min as shown in 
Figure (2.5) with stirring speed of 250 rpm. DOX was added to the CS-PEG mixture while 
maintaining light protective performing conditions. Four different concentrations of DOX were 
used; 1.25 µg/mL, 2.5 µg/mL, 5 µg/mL and 10 µg/ml. Four different drug concentrations were 
obtained by the end of this step. The color of the four solutions were varied with red color intensity 
according to their corresponding concentration. The drug-copolymers were left for homogenous 
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mixing in order to achieve complete chemical interaction between the positive amino NH2 group 
of DOX and negative polyanion of TPP, likewise the noncovalent encapsulation between DOX 
and of CS / PEG polymers. They were left for 1 hour within a mild stirring speed of 250 rpm. This 
period of time was quiet enough to allow efficient interaction capability between DOX, TPP and 
the polymers. 
 
Figure 2.5: illustrative scheme for encapsulation of DOX inside PEGylated CS NPs 
 
Finally, the polyanion TPP was added to the four solutions in order to allow sufficient cross-linking 
between DOX and the other polymers. The solutions were kept mixing under mild stirring 
conditions within a speed 250 rpm for 30 min. The formation of white turbid clouds inside the 
three solutions appeared instantaneously upon drop-wise addition of TPP under these mild stirring 
conditions. These whitish clouds, simply, represent aggregates of DOX loaded PEGylated CS NPs. 
These clouds were kept in light protected conditions to avoid photo-degradation of any remaining 
DOX.   
 
The formulated CS NPs were directly separated by using centrifuging parameters at 10,000 rpm 
for 30 min using HERMLE Labotechnic 36 HK (Germany) in order to be ready for further analysis 
and testing. The sedimented NPs required considerable multiple washing in order to ensure 
collecting pure DOX loaded CS NPs without any residue or unreacted chemicals. The unused 
supernatant was analyzed each time for measuring the amount of non-encapsulated DOX. CARY 
500 SCAN varian (Hi-tech, NJ, USA) UV-VIS spectrophotometer was used for characterizing the 
 52 
 
presence of DOX in the produced supernatants. The instrumental response for the supernatant at 
each round was plotted against the previously and basically issued regression equation of 
calibration curve of DOX.  
 
The fresh isolated pellets of DOX loaded CS NPs were divided into two main parts. The first part 
had vigorous mixing or redispersion of these formulated nanoparticles in a fresh media, like 
distilled water, using ultrasonic probe sonicator; Ploytron (Thermo Fisher, USA). The applied 
sonication parameters were 50% Amplitude for 3-5 min. The sonicated part of NPs was, then, 
diluted with distilled water so as to provide a liquid nano-system with a concentration of 1mg/ml. 
This DOX loaded CS NPs suspension was characterized later for particles’ surface morphology, 
shape, size, distribution and zeta potential using TEM and DLS. The second part was characterized 
for the chemical interaction between DOX with the applied polymers using FTIR (Thermo Fisher 
Scientific Nicolet 380 Spectrophotometer, USA). For this purpose, the second part of the NPs 
pellet was freeze-dried using BIOBASE freeze drier (Jinan, China) (see appendix SI 4.2).  
 
2.6. Conjugation of Monoclonal Antibodies (mAbs): 
 
Attaching biological ligands to the surfaces of the nanoparticles was expected in enhance the 
specificity and sensitivity of the entire nanocarrier. Anti-Human Epidermal Growth Factor 
Receptors (Anti-HER2) and Anti Human Mammaglobin antibody (Anti-hMAM) have been 
suggested to be used as the targeting moieties. Such conjugation my promote the cancerous 
endocytosis and cancerous sell uptake. In turn, it may minimize the normal cells attachment. This 
has been expected to decrease the systemic adverse drug reactions that are of the entrapped DOX 
drug and minimize its oxidative cardiotoxicity. The conjugation of the mAbs has been done 
according to collected procedure using some previous reports (130, 131).  
 
 
In this sense, after selecting the nano-formula with 5 Ug/ml Loaded DOX, the nanoparticles have 
been freeze dried. EDC has been used to activate the COOH gp on the surfaces of DOX loaded 
PEGylated CSNP. After around 15 minutes slight mixing, centrifugation of the solution has 
resulted in a pellet of nanoparticles that have activated COOH group on the surface. BPS has been 
used for washing the nanoparticles to remove the excess EDC. On the other side, mAbs has been 
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shacked with micropipette and then was introduced to the nanoparticles mixed with EDC. EDC is 
extremely hygroscopic; therefore, its storage should be highly considered (132).  
 
Then mAbs have been mixed to the COOH activated nanoparticles. They have been left on the 
orbital shaker with slight speed of 150 RPM for 2 hours. Then the two samples with two separates 
different mAbs have been centrifuged at 20,000 RPM for 30 minutes. Then PBS has been used for 
washing for 2 times at least with 5 minutes centrifuging at 8000 RPM.  The resulted pellet has 
been resuspended in fresh PBS with slight shaking in order to resuspend the nanoparticles with 
surface conjugated mAbs. The ratios between the chemicals were different. For instance, the ratio 
between EDC to the nanoparticles was 5:1 and the ratio between nanoparticles and mAbs was 
1:50. HNMR spectrum and FTIR spectrum have been conducted to ensure the surface conjugation 
of these mAbs. Besides, TEM imaging have been conducted as well in order for confirming the 
surface decoration and spherical shape of the resulted nano-systems.   
 
Degree of substitution (DS) = 
𝑀𝑜𝑑(COOH)
𝑇𝑜𝑡 (COOH) 
 ×  100    ……. Eq. (2.1) (246) 
 
 2.7. Characterization of CSNPs, PEGylated CSNPs and DOX loaded 
PEGylated CSNPs: 
 
2.7.1. Dynamic light scattering (DLS): 
 
 The main application of criteria of the NPs were the smallest size, least aggregation tendency and 
smallest PDI value as measured by Dynamic light scattering (DLS) enhanced Zeta sizer 
instrument. The concentration of all different samples was kept constant at 1mg/ml.  
 
2.7.2. Electrophoretic light scattering: 
 
In the current study, we mainly used zeta potential analysis during different phases of the study in 
order for investigating the surface charges of the resulted CS NPs, PEGylated CS NPs and DOX 
loaded CSNPs. Any variation in the surface zeta potential indicated a change in the surface 
structure, which was a good indicator of surface attachment and hence the charge density would 
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be affected with that attachment and the stability rate of the prepared NPs. The higher the value of 
zeta potential, whether positive or negative, the higher the tendency of the colloidal dispersion to 
resist particles attraction or aggregation. The information obtained from zeta potential analysis 
have had a good directionality of which sample will be more stable and more efficient to be a 
platform for DOX drug delivery.   
2.7.3. Fourier transform Infrared (FTIR) spectroscopy: 
 
FTIR spectroscopy was applied using FTIR (Thermo Fisher Scientific, Nicolet 380) 
spectrophotometer to develop a graphical fingerprint of the chemical structures of the control 
nanoparticulate samples (CS, TPP and PEG), to be compared with the prepared nano-formulations 
including CS NPs, PEGylated CS NPs and DOX loaded CS NPs. The samples were lyophilized 
for at least 72 hours under -60 C temperature. Then KBr was used with all samples to prepare the 
sample pellet. KBr was lyophilized first in order not to affect the sample absorbance since KBr is 
optically transparent, and acts as inactive sample carrier within the IR region (133).  
 
2.7.4.  X-Ray Diffraction Spectroscopy:  
 
XRD spectroscopy analysis were carried out using Bruker D8 (MS, USA) in order to investigate 
the internal crystalline structures of all samples including the cross-linked CS NPs, and PEGylated 
CS NPs. The linkage of some polymers like TPP and PEG would provide some effect on the entire 
crystalline structure of CS. Therefore, the entrapment efficiency of these polymers would be shown 
with XRD analysis.  
 
2.7.5.  Scanning Electron Microscopy (SEM):  
 
The particle’s morphology and size of the produced NPs with attachment of PEG were 
characterized by using SEM. The primary characterization of CSNP and PEGylated CSNP was 
done with an oven dried sample. These samples were diluted as 1mg/mL, and then moved to a 
spread aluminum sheet, over which it was dried at 60C temperature for 10 min. After drying, the 
sample was gold sputtered for 15 min so that the surface of the sample become conductive and, 
hence, interact with the bombarded electrons and also to enhance the resolution and quality of the 
images.     
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2.7.6. Transmission Electron Microscopy (TEM): 
 
TEM analysis were performed using Ultra-High Resolution schotty Transmission Electron 
Microscope SU 7000. The preparation of TEM sample was done with diluting the prepared 
solutions to 0.02 mg/mL. Three different types of samples; CS NPs, PEGylated CS NPs and DOX 
loaded PEGylated CS NPs were prepared. The provided information by TEM images was related 
to the morphology, topography, size and particle distribution was helpful to show the successful 
attachment of PEG and DOX. One drop of the diluted sample was dried and dyed with 
phosphotungestin dye to keep the surface of the nanoparticles conductive; and therefore, the 
electrons can be captured easily resulting in better image resolution.   
2.7.7. UV-Vis Spectroscopy: 
 
UV-Vis spectroscopy analysis were performed using CARY500 SCAN Varian UV-VIS 
spectrometer (Hi-tech, NJ, USA) for different characterizations analysis that were related to DOX 
concentrations. First, a calibration curve of 6 different concentration of DOX aqueous solution 
using deionized water was plotted. Then, the absorbance of the unloaded free DOX that was 
measured in the supernatant of DOX loaded CSNP preparation was determined at wavelength of 
480 nm using clear quartz processing cell. This allowed the determination of the loading capacity 
of such NPs relative to very minute concentrations of DOX that were reaching few micro liters. 
Besides, the release profile of DOX loaded CS NPs has been detected with the same UV 
spectrophotometer. PEGylated CS NPs was used as a black. The scattering of UV-Vis light beam 
that was done by such PEGylated CSNP solution was excluded. Moreover, the UV-Vis absorption 
of many different samples with various concentrations that were related to various time slots were 
analyzed in order to reveal the releasing behavior of the nano formulations.  
 
2.8. Drug Loading, Release Profile and Stability of NPs:  
 
2.8.1. Drug loading: 
 
Loading of DOX to PEGylated CS NPs was performed using different weights of DOX; 0.125 mg, 
0.25 mg, 0.5 mg and 1 mg in order to define the most suitable drug concentration that could achieve 
the best loading capacity. DOX loaded PEGylated CS NPs were dissolved in PBS medium and 
kept on stirrer for 24 hours at 100 rpm. This was done within light protected environment under 
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ambient temperature. Thereafter, the DOX loaded NPs were centrifuged at 20,000 RPM for 30 
min under 4 ºC temperature. The concentration of free DOX drug in the supernatant layer was 
detected using UV-Vis spectroscopic analysis at wavelength of 482 nm. Drug loading capacity has 
been detected using the given equation (Eq. 2.2).  
 
Loading capacity (LC%) = 
(𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑−𝑑𝑟𝑢𝑔 𝑖𝑛 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡)
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
 ×  100  …... Eq. (2.2) (134) 
 
Encapsulation efficiency =
(𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑−𝑑𝑟𝑢𝑔 𝑖𝑛 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡)
𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑
 ×  100  …….Eq. (2.3) (134) 
 
 2.8.2. Swelling test: 
CSNP has been shown by many studies to have a swelling tendency which may differ according 
to the pH of the dispersive media (135). Swelling test in the current study has been performed in 
order to assess the influence of various pH levels on the swelling of the DOX loaded PEGylated 
CSNP and predict their effect on the entrapped drug. Therefore, swelling indices have been 
calculated for the nanoparticles in two different pH media; 6.6 and 7.4. These two specific pH 
media are two model values that are related to the breast tumor pH and normal blood pH levels 
respectively (136). Swelling index has been obtained using the given equation Eq. (2.4), where Sw 
is the swelling of the nanoparticles after time t, Wo is the weight of nanoparticles before incubation 
or in a dry form and Wt is the weight of nanoparticles after time t or after incubation time. 
 % Sw =
Wt −W0
W0  
× 100          ……. Eq. )2.4) (137) 
 
2.8.3. Stability of DOX PEGylated CS NPs: 
 
The highest LC% of DOX was determined from the previous experiments. Thereafter, the stability 
profile of the highest DOX loaded sample was investigated. The stability of the samples was 
confirmed after incubation in BPS of pH 7.4 for two weeks at 37 ºC. UV-Vis spectroscopy was 
applied to detect the release profile of DOX by measuring its concentration at wavelength of 480 
nm.  
 
 
 57 
 
2.8.4. Drug Release Profile: 
 
Release profile of the highest DOX loaded PEGylated CS NPs was studied. The sample was tested 
in two different pH media. The first one mimicking the normal blood circulatory pH 7.4, while the 
second one was mimicking the tumor microenvironment pH 6.6. The samples were kept inside the 
incubator for around 72 hours at 37 ºC temperature. Within various time intervals, the 
concentration of the released DOX was determined by using UV-Vis spectroscopy as well at 
wavelength of 480 nm. The applied time slots were (1, 3, 6, 9, 12, 18. 24, 36, 48 and 72) hours. 
Re-compensation for the withdrawn amount with another fresh media was carried out. 
2.9. Cell culture analysis: 
 
2.9.1. Cell line maintenance: 
The anticancer activity of the fabricated CS NPs, CS NPs-PEG, and CS NPs/DOX was analysed 
in-vitro against human isolated breast cancer cell line (MCF-7) and a normal mouse fibroblast cell 
line (L929). The cell lines were propagated as a monolayer separately in DMEM. They were 
passaged three times per week in 75 cm2 cell culture flasks and safely incubated at 37°C  in 5% 
CO2 incubator. Regular cell detachment was proceeded before passaging times and the specified 
MTT assays using trypsin (0.25%) containing 0.1% EDTA. Trypan blue has been applied in cell 
counting using hemocytometer.  
 
2.9.2. Direct Cytotoxicity (MTT assay):  
The anticancer property of DOX before and after encapsulation inside CS NPs against MCF-7 
cells and the cyto-compatibility of fabricated samples against L-929 cells were investigated based 
on ISO10993-5 standard procedure (138). Colorimetric 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide dye analysis (MTT cell viability analysis) has been used to detect the 
viability profile of both types of cells with 24 hrs incubation in a 96 well plate. In order to attain a 
semi-confluent cell growth after 24 hrs; MCF-7 cells seeded at density of 25 × 103 cells/well, while 
L-929 cells seeded at density of 3 × 103 cells/ well in 96 well plate. Following that, a direct addition 
of 50 ul/well from previously prepared serial dilutions of CS NPs, CS NPs-PEG, and CS NPs/DOX 
(1.25, 2.5, 5 and 10) µg/ mL. After 24 hrs, MTT reagent has been used to replace the media with 
1 mg/ml conc. The replacing volume was 100 µl that has been incubated for 4 hours. PBS was 
used for washing and removal of MTT medium. This washing process was done tow times. 100 
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µl of 100% DMSO was applied in order to dissolve insoluble Formazan crystalline products, that 
are expected to be cytotoxic and damaging to the cells.  A microplate reader (SPECTROstar Nano, 
BMG LABTECH, Germany) has been used at Abs of 570 nm to detect the cell viability. Control 
sample has showed 100% viability, while the viability of the remaining wells has been identified 
using Eq. (2.5) 
 
Cell Viability Rate =
Sample ABS
Control ABS 
× 100          ……. Eq. (2.5) (139) 
 
2.10. Theoretical background: 
2.10.1. Zeta-Sizer and Zeta-Potential (MALVERN) : 
This is a main dual systematic instrument that includes both dynamic light scattering (DLS) that 
is used to assess the nanoparticle’s sizes and distribution, and electrophoretic light scattering (ELS) 
that is used to determine the surface charge of a particles within a solution medium.  
 
 
Figure 2.6: Systematic setup of the basic principle for dynamic light scattering with detecting different scattering 
angles of the laser beam (140) 
 
The basic principle of DLS is simple as a monochromatic laser beam is directed towards the sample 
cuvette. When the incident laser beam illuminates the particles in the cuvette, it gets scattered in 
all directions. A photon detector is used to receive the scattered light beam at a certain scattering 
angle . In another words, when the particles scatter the laser beam, they provide information about 
their size, motion and distribution. Physically, the scattering is related to the hydrodynamic radius 
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(Rh) of the particles (141). The correlation of the laser scattering intensity is done through software 
analysis or the digital correlator as shown in the DLS scheme in Figure (2.7).  
 
 
Figure 2.7: Illustrative description of different components of dynamic light scattering instrument (141) 
 
By defining the diffusion parameters from Eq. (2.6), we can calculate the hydrodynamic radius Rh 
that corresponds to the particles size. D represents diffusion coefficient, kB represents Boltzmann 
constant, while T is the temperature and n is the sample viscosity of the sample. By defining such 
parameters, we can calculate the. The concentration of the sample should be very low, because 
this equation is valid for single scattered light. When sample’s concentration is too high, multiple 
scattering occur and this equation become invalid.      
         
                                                                                               ……… Eq. (2.6) (143)                                     
 
The surface charge of any nanoparticle is a key indicator of the aggregation or stability tendency. 
Zeta potential represent the electro-kinetic potential of nanoparticles or any other particles in 
general within a colloidal system. The higher the charge value on the particles surface, the more 
stability suspension or colloidal system.  
 
The electrophoretic light scattering instrument is processing with an electric field is applied the 
sample cell. This electric filed cause the particles to move because of the interaction between them. 
Through this interaction between the particles and the applied field, they acquire some charge. 
This charge affects the speed and direction of particles movement. Besides, the strength of the 
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applied electrical field and the nature of the colloidal medium are two important factors also that 
affect them (144). 
 
 
(A)                                                                  (B)  
Figure 2.8: Schematic diagram showing the principle of electrophoretic light scattering with a multiple layer of 
illustrative charged layers (A), and the shape of the sample cell kit (B) (144) 
 
2.10.2. Fourier Transform Infrared (FTIR) Spectroscopy:  
 
It is one of the well-known analytical techniques that is mainly used to characterize various 
materials types including organic, in-organic and polymeric chemical materials. The change in the 
surface structure or surface functional group(s) can be monitored and analyzed by FTIR. This 
allow us to understand the significant change of the physico-chemical properties of the material 
after addition of certain polymer or chemical substance to the surface or the core of the main 
material. Besides, the durability and structural stability of a material can be another feature that 
can be easily monitored through FTIR (145).  
 
Some characteristic structural moieties of a chemical material can be represented in a specific 
pattern within a certain range of infra-red absorbance value. Analytically, the ability of these 
moieties to absorb the incident infra-red spectrum in the range of 400 to 4000 provide a graphical 
analysis of the chemical information of the applied sample. through FTIR, we can also release a 
chemical comparison between the polymerized material and the original or the standard ones 
through the intensity, position and behavior of the absorption peaks. It can be used, also, to identify 
material’s decomposition, oxidation, deterioration or any undesired contaminants. Therefore, 
 61 
 
FTIR can provide a rigid justification that supports a successful change in the chemical and 
physical properties of the applied material (146).  
 
 
Figure 2.9: schematic representation of the FTIR working principle (147) 
 
The working principle of FTIR is mainly focusing on the interaction between the sample material 
and a light source within the infrared region in a surrounding electromagnetic field. Once the 
sample disc is subjected to the IR light, it absorbs the light and get excited. The inner structural 
molecules are excited also and moving to a higher vibrational level at a certain frequency. The 
energy difference between the ground energy level and excitation level is basically equal to the 
light energy that the molecules have absorbed.  
 
Light is sent to the sample through an instrumental device called interferometer. The IR radiation 
is sent to the sample material through a beam splitter. As a result, the radiation light is divided into 
two halves. The first one is going to a fixed mirror, while the second half is going to a continuously 
moving mirror. Then the two split beams recombine again at the detector and pass through the 
sample again. In this case, the sample absorb all characteristic wavelengths, in an interference 
pattern, from the interferogram. The energy variation is detected through the detector which read 
it versus time.  Through Fourier Transform mathematical technique, a software generated 
procedure provides a relationship between time and frequency. This relationship is identified later 
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with against referenced libraries that develop the spectrum information of the sample that is 
considered as a fingerprint for such specific material (148).  
 
2.10.3. X-ray diffraction:  
 
X-ray diffraction is advanced new characterization techniques that is used to analyze a crystalline 
material and studying its atomic spacing as well. Besides three-dimension structural analysis, XRD 
is efficient also to study a unit cell dimensions. XRD is mainly based on the interaction between 
X-rays and a crystalline sample. the main source of X-rays emission is a cathode ray tube that is 
directed to the sample with a monochromatic radiation pattern. When the X-rays hit the powdered 
sample, it diffracts with a diffraction angle  (149). This constructive interference and the 
relationship between the angle of diffraction  and the electromagnetic radiation wavelength is 
expressed as Bragg’s law that is shown in (figure 2.10) and Eq.2.  
 
nλ=2d sin θ.                    …… Eq. (2.7) (150) 
 
Where θ is the scattering angle or the angle between the incident X-ray beam and the lattice plane, 
 is the wavelength of the incident electromagnetic waves, d is the interplanar distance (Figure 
2.10). n represents the positive integer factor or the order of reflection.  
 
 
 
 
 
 
 
 
 
Figure 2.10: illustrative scheme of X-ray diffraction with diffraction angle θ (Bragg’s law) (151) 
 
The X-ray cathode tube produces an X-ray beam by heating the filament of the tube that produces 
a series of electrons. These electrons are directed towards the sample material and accelerated by 
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applying voltage. These electrons are going to bombard the sample and expel its inner shell 
electrons as shown in (figure 2.11). In order to do that, the incident electrons must have sufficient 
high energy. By dislodging the inner shell electrons, X-ray is emitted. A crystal monochromator 
is used to produce monochromatic rays. As the sample and X-ray detector are rotated, the 
diffracted emissions are recorded by the processing detector. When the dimensional arrangement 
of the incident rays satisfies Bragg’s law, the detector record the signal and convert it to 
mathematical counts that is illustrated through a computer monitor (152).  
 
Figure 2.11: X-ray beam bombarding the Inner shell electrons (152)  
 
2.10.4. Ultra-Violet / Visible Spectroscopy:  
UV-Vis spectroscopy is a frequently used characterization analyses that mainly target the optical 
properties of different samples. Through this analysis technique, we can develop qualitative and 
quantitative analysis, detect the presence of undesired impurities and detect the presence or 
absence of certain compositional functional groups. Generally, the electromagnetic spectrum of 
sunlight consists of a range of radiation regions including the UV-Vis region which is located at 
the range of 210-900 nm.  The interaction of the sample to light in this region is the principle 
source of UV-Vis spectroscopic analysis. When light hit the sample’s molecules, the atomic 
electronic transition takes place immediately between different energy levels or, typically, from 
the higher occupied molecular orbital (HUMO) or ground state to lower unoccupied molecular 
orbital (LUMO) or excited state as shown in (figure 2.12). This intermolecular transition is 
accompanied by absorption of electromagnetic radiation in this region. 
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Figure 2.12: The electronic excitation by absorbing high energy UV light spectrum (153) 
 
HUMO and LUMO orbitals are called also bonding shells and antibonding shells, and the 
difference between them is known as band gap. In order for absorption to take place, the UV light 
photons must have energy amount that matches to this band gap. In this concern, different 
molecules will definitely have different band gap energies and, therefore, will have different 
absorption spectra. Once the sample was hit with a beam of UV light, it absorbs part of it and the 
intensity of the released beam will exponentially decreased as shown in (figure 2.13) and 
absorbance equation Eq. (6). However, the transmittance has the same relationship between the 
incident light (Iº) and the transmitted light (I), but absorbance is the counteractive principle of 
transmittance.  
𝑇 = 𝐼/𝐼°                     …….. Eq. (2.8) (154) 
𝐴 = log 10  
𝐼°
𝐼
      ……… Eq. (2.9) (154) 
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Figure 2.13: The transmittance of UV light beam through a sample (154) 
 
UV-VIS spectroscopy is mainly based on the ability of measuring the spectrum of a certain sample 
containing chromophore or light absorbing molecules. This allow us to obtain a graphical 
relationship between the wavelength or frequency at which light is absorbed, and the absorption 
rate that is detected by the amount of chromophore exist in the sample. therefore, the higher the 
amount of this chromophore in the applied sample, the more dense the amount of the absorbed 
light. This relationship reveals another direct relationship between the sample concentration and 
wavelength or frequency of the emitted UV light. Beer’s Lambart law has exploited this optical 
relationship in order to develop a linear relationship between concentration and absorbance as 
shown in Eq (7).   
𝐴 =  ℰ 𝑐 𝑙      ……… Eq. (2.10) (155) 
A: the absorbance  
ℰ: absorption coefficient  
c: molar concentration of the solute  
l: path length   
This equation (Beer’s Lambart law) can be used analytically to relates the concentration of a 
substance in a sample to the color intensity of the same sample. when we have large number of 
samples and different concentration in each sample, we can use the developed linear relationship 
that this law provides. However, we need first to issue a calibration curve. This calibration or 
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regression curve is based on plotting 3 to 4 concentrations of the sample and getting their 
corresponding absorbance values. This plot will work as a reference from which we can obtain the 
concentration of any unknown concentration of the same sample (155).  
 
Figure 2.14: schematic representation of UV-VIS spectrometer principle (154) 
 
2.10.5.  Scanning Electron Microscopy (SEM): 
 
SEM is a powerful and reliable analysis techniques that is used for imaging samples. This 
technique is much advanced than simple light microscope since it uses electrons to image the 
sample unlike light microscope that use light. The wavelength of electrons is much smaller than 
that of light, therefore the magnification and resolution of SEM is more preferred than traditional 
light microscope. SEM provides such electron-oriented magnification through the use of a set of 
coils that scan the electrons bombarded from the sample (156).  
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Figure 2.15: Multi pin sample’s holder carrying different aluminum foils with spread samples for TEM imaging 
(157) 
 
As shown in (figure 2.16), the raster pattern of the coils is used to scan the sample through the 
generated electrons for the electron source at the top of the instrument. Basically, these electrons 
are produced when their thermal energy exceed that of the main electron sources. The role of the 
positive anode that is fixed below the electron source is to attract and accelerate the speed of the 
emitted electrons under protective vacuum. This vacuum has a critical indirect effect on the overall 
quality of the released images by protecting the electrons from interacting with any external atoms, 
molecules, noise or contamination (158). On the other hand, the use of such condenser lens and 
objective lens is mainly applied for adjusting the electron path, and this ends up with controlling 
the resolution. The integration of apertures may be considered in some SEM systems in order to 
control the size of the beam and control the current as well. This may give a good opportunity for 
controlling the resolution of the resulted images (159). Typically, the main use of SEM is to 
analyze different types of samples such as insulating, thin organic, biological and vacuum sensitive 
samples with satisfying resolution and magnification power.  
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Figure 2.16: Illustrative description of SEM unite with variable (160) 
2.10.6. Transmission Electron Microscopy (TEM): 
TEM is a powerful and versatile tool for imaging of many different types of samples. It is widely 
used in biological fields, forensic analysis, material sciences, medical and nanotechnology 
applications. The main use of TEM is to provide some information about the crystalline structure, 
size, particles distribution, morphological, chemical structure, structural defects and topographical 
properties. Similar to SEM, the source of these information is basically dependent on the 
interaction of the sample to a very high energy electron beam that is much stronger than SEM. The 
electron beam is accelerated with applying voltage approximately more than 200Kv. The electrons 
are accelerated to a very high speed near the speed of light. While the wavelength of the electrons 
in the electron beam is million times shorter than normal electromagnetic wavelength of light, the 
spatial resolution and magnification quality of TEM images is much higher than normal light 
microscopy (161). 
TEM is operated in a similar process to the simple light microscope. However, TEM uses a stream 
of electrons produced by an electron gun (figure 2.17) instead of using light source. The electron 
beam is directed towards the sample in a very high speed that is enough to pass through the sample. 
A primary condenser lens is used to focus the emitted electrons into a thin and coherent electron 
beam. Once the electrons could pass through the sample, they are scattered. These scattered 
electrons are then focused by an electromagnetic lens called objective lens. This lens focuses the 
received electrons into an image that is transmitted through a projector lens. This projector lens is 
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used mainly to expand the electron beam into a monitor or camera supported projector so that the 
image is seen by the user (162).  
 
Figure 2.17:  Schematic representation of the different components of TEM (163) 
Table 2.4: comparison between TEM and SEM (162-164) 
Item TEM SEM 
Sample Very thin Thick and conductive 
Resolution Very high, ~ 0.5 Aº High, ~ 0.5 nm 
Electron beam Pass through the sample Surface analysis 
Sample preparation Extensive Simple 
Surface modification Dyeing Gold sputtering 
Voltage Very high Medium 
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Chapter 3 
 
Results and Discussion 
 
Synthesis and Characterization of  
PEGylated Chitosan / 
Doxorubicin Nanoparticles 
and Conjugated with Monoclonal 
Antibodies for Breast Cancer Therapy  
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3.1.  Preparation of CSNP: 
 
 
In order to successfully prepare a conjugated drug delivery system that is effective against breast 
cancer, CSNP have been used to encapsulate anticancer drug like DOX, and the nano-system was 
further conjugated with monoclonal antibodies. Several parameters have been considered and 
found to have considerable effects on the preparation of the final formulations such as: particles 
size, size distribution, surface charge, stability in different pH media, surface functionalization, 
physiological circulation time, biocompatibility, biodegradability, swelling matrix, and drug 
diffusion rate. Ionotropic gelation method was used to prepare CSNP due to its efficiency and the 
resulted high particles’ stability for longer periods (165).  
 
 
3.1.1. Ionotropic Gelation: 
 
 
As shown in Table (3.1), the integration of different concentrations of CS polymer and TPP, as a 
cross-linker, for preparation of CSNP. TPP has been shown to be biologically safe, non-toxic and 
non-carcinogenic owing to its hydrolyzed phosphate ions (166). The resulted CSNP in Table (3.2) 
had various sizes and PDI values. Moreover, the final appearance of the formulated CSNP was 
slightly different from each other. Some samples have shown whitish uniform colloidal systems 
of suspended CSNP. While others have shown high tendencies of particles aggregation with 
whitish turbid solution (112).    
 
Table 3.1: Variation of sample formulas according to chitosan and TPP concentrations 
 
 
TPP conc 
(%)  
Chitosan concentration (%) 
0.05 0.1 0.5 1 
0.1 S1 S2 S3 S4 
0.3 S5 S6 S7 S8 
0.5 S9 S10 S11 S12 
0.7 S13 S14 S15 S16 
 
The polymeric matrix of CSNP, by ionic gelation technique, is controlled and tunable through an 
electrostatic interaction between (+vely) charged NH2
+ from CS and (-vely) charged polyanions 
from TPP (166). This gelling formation interaction has been found to be affected by the 
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concentrations of the two polymers, and the resulted particles sizes are, also, affected as shown in 
Table (3.2).  
Table 3.2: Particle size and distribution of different samples with various concentrations of TPP and chitosan 
 
 
 
 
 
 
 
 
 
 
 
 
 
By demonstrating all of these previous results, sample 8 has been the sample of choice. It has 
demonstrated the smallest size with acceptable poly dispersity index. The applied CS:TPP ratio has 
been close to 3:1. The size of this sample has been 190 ± 5.6 with a good particle’s distribution of PDI 
0.51 ± 0.002. Biologically, this size can develop many pharmacokinetic and therapeutic benefits 
compared to larger sized drug carriers (112). Many factors have been shown to affect the size and PDI 
of the resulted CSNP such as processing pH and deacetylation degree of CS (167). Therefore, the effect 
of these parameters has been explored on this sample.   
3.1.2. Factors affecting size of CSNP:   
 
 
Figure 3.1: Effect of processing pH (A) and deacetylation degree (B) of CS on the size of CSNP 
Sample Particle size (nm) PDI 
S1 3668.6 ± 967.6 0.31 ± 0.17 
S2 4986 ± 1300 0.64 ± 0.07 
S3 1607 ± 63.66 0.43 ± 0.01 
S4 518.76 ± 28.28 0.86 ± 0.05 
S5 1594.5 ± 195.8 0.86 ± 0.02 
S6 3894 ± 376.7 0.69 ± 0.26 
S7 1582.5 ± 228.3 1.37 ± 0.36 
S8 190 ± 5.6 0.15 ± 0.02 
S9 1979.5 ± 64.3 0.22 ± 0.05 
S10 1895 ± 161.3 0.41 ± 0.07 
S11  678.66 ± 15.02 0.85 ± 0.06 
S12 690.9 ± 28.42 0.24 ± 0.02 
S13 5645.3 ± 685.5 0.45 ± 0.11 
S14 2362 ± 678.34 0.24 ± 0.06 
S15 2265.6 ± 141.78 1.33 ± 0.31 
S16 1300.6 ± 664.8 0.66 ± 0.32 
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o Processing pH: 
Size has been shown to be decreased with decreasing the processing pH media. That’s may be 
because of the high protonation rate at highly acidic media. It increases the reactivity of the 
terminal NH2 groups of chitosan and improve the ionic strength of the dissolution media (168). 
Therefore, the lower the pH value, the lower the size we have as shown in Figure (3.1A). However, 
the distribution of the resulted particles has been non uniform with high PDI value of the resulted 
CSNP. Consequently, lowest pH media are not always the best solution, the current study 
recommends adjusting pH of the processing medium to 5 (169).  
 
o Deacetylation degree:  
On the other hand, degree of deacetylation is another critical factor that has been discussed with 
many published reports (170). The results of the current work have revealed that sizes of CSNP 
decrease as the degree of deacetylation of CS increases as shown in Figure (3.1B). This may be 
related to the amount of deacetylated amine groups. In another words, high deacetylation degree 
provides high density of positive NH2
+ charged groups. This high positive charge density enhances 
higher crosslinking interaction with TPP. Although, this may contradict with Vivek et al. that 
proposed that the surface charge of CSNP is -35 (171), however, Phaechamud et al. and Ling et al 
agreed on this (172). Therefore, CS with high deacetylation degree has been used in the current 
study.  
 
o CS: TPP ratio:  
The relationship between CSNP’s size increment and TPP concentration has been demonstrated 
in Figure (3.2). Whenever the concentration of TPP is increased or decreased than the selected 
concentration (0.3%), the sizes and PDI of the resulted CSNP are going to massively increase with 
having some of them reaching micro sized ranges. 
 
When TPP concentration is over increased, the cross-linking rate of CS is increased. That’s may 
be due to the accumulation of the excess TPP molecules upon the outer surfaces of the already 
crosslinked CSNP. This may enhance more intramolecular interaction, and higher occupation rate 
of free NH2
+ groups of chitosan by TPP. This can provide what is called oversaturation of CSNP’s 
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surface and become more reactive to proceed another cross-linking process. Therefore, the size 
becomes greater 
 
Figure 3.2: Effect of TPP concentration on the final size of CSNP 
 
On the other side, at very lower TPP concentrations, the size of the crosslinked CSNP tends to 
increase, and whitish turbid clouds are seen in the preparation media. At very high conc of CS 
relative to lower TPP, neutralization of the protonated cationic NH2
+ groups of CS by TPP is 
decreased, and this led to higher sedimentation rate of chitosan polymer, especially, when chitosan 
acidic solution is rich with acetic acid (113, 173). Therefore, the current work may conclude that 
there is an optimum ration of CS: TPP which is expected to be near 3:1 (168). 
3.1.3. Stability of the selected CSNP sample:  
 
Surface charge of CSNP is a remarkable factor that is considered as an indicative factor of the 
particle’s stability and their tendency to form aggregates. The colloidal suspending appearance of 
CSNP is highly affected by the charge on their surfaces. This charge is influenced by the same 
previous parameters (174, 175). In order to make sure of the surface stability of the selected CSNP 
sample; S8, a three weeks stability profile has been developed as shown in Figure (3.3).  
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Figure 3.3: Stability profile of the selected CSNP sample; S8 for three weeks at pH 7.4 
 
Furthermore, size stability profile has been confirmed with calculating size increment percentage, 
which is an indication of size variation along the stability period of time. It has been calculated 
according to the given equation (Eq.3.1). Owing to the high charge surface positive zeta potential 
value of the selected CSNP sample with Zeta value of 42.8 mEv, the particles have been shown to 
have a small size increment percentage as 8.9%. That because of a direct relationship between 
having high zeta potential value and showing a good stability profile for longer time (166).  
 
Size increment % =
Size at the biginning −Size after 22 days
Size at the beginning  
× 100          ……. Eq. (166)  
 
Finally, the size of the developed CSNP as drug carrier is a substantial factor that needs to be 
studied very well before drug encapsulation or PEGylation process. This has a strong influence on 
the efficiency of the developed drug delivery system. As the size of the nanoparticles decreases, 
the drug cellular uptake increases. Besides, a direct relationship between nanoparticle size and 
pharmacokinetic drug distribution is considered. Nanoparticles’ sizes below 100 nm have 6-fold 
more cellular uptake rate than micro sized particles (177). Furthermore, CSNP within a size range 
less than 200 nm provided more potent dosage forms than larger micro range particles. The 
advantages of nanoparticles in this size ranges are enhanced muco-adhesion, biocompatibility, 
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increased therapeutic index, enhanced stability and less carcinogenicity. This has been consistent 
with Pawar et al, that could achieve > 95% drug entrapment efficiency within a size range (100 – 
200) nm (178). Therefore, the recommended size of the prepared CSNP in the current study has 
been less than 200 nm.  
  
 
3.2. PEGylation of CSNP: 
 
Coating of the prepared CSNP’s surface with PEG has been reported in many studies showing 
high NP surface stability and solubilization. The increased blood circulation time and 
immunological RES resistance of CSNP that are coated with PEG is a guiding factor for seeking 
PEGylation process. PEG aims to protect CSNP by blocking their surface positive charges that 
can be included in the opsonization process by RES (179, 180).  
 
Table 3.3: Size, PDI and zeta potential of PEGylated CSNPs  
 
 
Samples  Size PDI Zeta Pot. 
Control (CSNP) 192 ± 4.1 0.19 ± 0.01 +43 ev ± 0.4  
CSNP-PEG 1% 175 ±4.8 0.25 ± 0.03 + 41.8 ev ± 0.6 
CSNP-PEG 5% 169 ± 5.8 0.15 ±0.01 + 35.6 ev ± 1.1 
CSNP-PEG 10% 173 ± 2.9 0.21 ± 0.02 + 39 ev± 1.2  
 
Table (3.3) provides the results of PEGylation process using various concentrations of PEG; 1%, 
5% and 10%. The resulted PEGylated CSNP have had various sizes, PDI and zeta potential values. 
The surprising observation about the PEGylated CSNP is that their sizes were found to be smaller 
than those free non-PEGylated CSNP by 8.7%, 12% and 9.8% respectively. This can be 
demonstrated by the effect of PEG surface brushes acting as colloidal stabilizer on CSNP surfaces. 
Moreover, the polymeric layer of PEG has provided “stearic stability” upon conjugation to the 
surface of CSNP. This has affected their size, PDI and surface zeta potential values (181). 
 
PEG forms an internal structural network with chitosan which is known as semi interpenetrating 
network (IPN) (112). This network has been proposed to be formulated during crosslinking of 
chitosan. It can increase the stabilization and compactness of the surfaces of CSNP. Therefore, 
 77 
 
their sizes and surfaces charges decrease after PEGylation. Besides, zeta potential value of CSNP 
has decreased because of the attribution of blocking surface terminal NH2
+ groups of chitosan and, 
thereby, decreasing their zeta potential values (182). 
 
The recommended PEG surface coverage with PEG conjugation has been attributed to 5% PEG 
concentration. The resulted nanoparticles have had lower size than 1% and 10% PEG 
concentrations. Besides, the particles distribution and surface charge values of the selected PEG 
concentration have pointed out its tendency to be stable. Assuming that further increase in PEG 
concentration can destabilize the nanoparticles due to the repulsive behaviors of the neighboring 
PEG chains (183). Further stability profile of the three PEG concentrations has been conducted in 
the current study as illustrated in Figure (3.4). PEGylated CSNP that have 5% PEG has been the 
most stable as referred by the blue arrow. While those with 10% PEG and 1% PEG were less 
stable.  
 
 
 
 
Figure 3.4: stability profile of PEGylated and non-Pegylated CSNP 
 
 
Basically, it is very rational to give high concern to surface stability issue of the PEGylated CSNP. 
Verreechia et al. has indicated its pharmacokinetic preference towards PEGylated CSNP with 
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stable surface conjugated PEG. The study has reported that PEGylated CSNP have higher blood 
plasma level with lower hepatic execration rates compared to non-PEGylated ones (184).  
 
The developed system in the current work tend to be positively charged, that aims to enhance its 
later electrostatic interaction to further tumor cells in the coming stages of the study. Generally, 
positive nano-carrier systems are not biologically favored, because they are easy to be captured by 
phagocytes and RES. Besides, they initiate electrostatic interaction with negative blood proteins 
(185). Furthermore, thrombogenic embolization and blood hemolysis are two adverse reactions 
that are expected to be initiated by positive systems.  
 
Therefore, grafting PEG can promote the biological safety and circulatory retention time of CSNP 
without casing such toxic adverse blood reactions. Furthermore, PEGylation improves the 
uniqueness of CSNP as an ideal nano carrier for later chemotherapeutic DOX encapsulation 
process. For instance, Clin et al. has reported higher liposomal accumulation of PEGylated DOX 
liposomes within a tumor area than non-PEGylated ones (186). This may affect the cancerous 
cellular drug uptake.  
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Figure 3.5: XRD pattern of Chitosan powder, CSNP and PEGylated CSNP 
 
The conjugation reaction or PEGylation of CSNP could be confirmed through XRD patterns of 
CS, CSNP, PEG, PEGylated CSNP as shown in Figure (3.5). Basically, this conjugation has been 
formulated between the amino group NH2
+ group from chitosan and C-O-C of PEG (187). This is 
in agreement with Calvo et al. that assumes, also, inter and intra molecular H-bonding between CS 
and PEG (112). The patterns show some representative peaks which indicates the crystalline 
behaviors of the tested structures. Chitosan powder, for instance, has two characteristic peaks at 
the angles of 21º and 10º as shown in the diffractogram, this demonstrated a high degree of 
crystallinity (188).  
 
On the other side, the diffractogram of CSNP shows no peaks, which is an indication of the 
destroyed crystalline structure of chitosan by TPP entry. This is related to the amorphous structure 
of CSNP which is composed of dense of cross linked counterions (188). In the diffractogram of 
 80 
 
PEGylated CSNP, the peak at 2θ of 10 º has been diminished. This is related to the decreased 
crystallinity of CSNP by the entry of PEG. The pattern of PEG has surpassed that of chitosan with 
its characteristic peaks at 19.12 º and 23.1 º, and this resulted in peaks shifting (189). Therefore, 
there is a good evidence for the efficient PEGylation of CSNP. 
 
 CSNP could maintain their spherical morphological shape after grafting of PEG on their surfaces. 
The PEGylation layer have demonstrated a brush like structure that surrounded CSNP. This has 
been confirmed with TEM pictures of both PEGylated; Figure (3.2 B and D) and non-PEGylated 
CSNP; Figure (3.6 A and C).  
 
 
 
 
 
 
 
 
 
 
 
 
      
B A 
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Figure 3.6: TEM image of Pegylated CSNP (B and D), non-PEGylated CSNP (A and C) and schematic illustration 
of the PEG layer that surround CSNP (E) 
 
3.3. Encapsulation of Doxorubicin: 
 
Doxorubicin has been selected as effective chemotherapeutic agent against all different types of 
breast cancer including both solid and soft tumors (190). DOX has been encapsulated successfully 
within the PEGylated CSNP via a pre-crosslinking entrapment. In other words, DOX has been 
introduced into CS-PEG solution before drop wise addition of TPP solution. Achieving good 
encapsulation with lower drug leakage has been fairly expected by the presence of PEG stabilizer. 
This enhances initiation of intramolecular hydrogen bonding between DOX and the reacting 
polymers (191). 
 
Slight mixing has been required besides pH adjustment from 5 to 6.5. This is assumed to enhance 
the entrapment of DOX inside the polymeric matrix. Both factors; the deprotonation pka of 
chitosan at 6.6, besides the hydrophilic nature of DOX promote more intracellular hydrogen 
interactions (192). Coinciding with that, PEG brushes are being maintained in order for enhancing 
the system biocompatibility (193). Non-covalent interaction is therapeutically more preferred than 
covenant entrapment (194). covalent interaction in a biological drug delivery system is more 
difficult to manage or predict  
 
3.3.1. DOX Standard Curve:  
 
Experimentally, variable concentrations of DOX have been fed in order to evaluate the highest 
loading and entrapment content of DOX; 1.25 µg/mL, 2.5 µg/mL, 5 µg/mL and 10 µg/mL. This 
has required a prior quantification of DOX, that has been issued by plotting its calibration curve. 
E  
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UV-VIS spectrophotometer has been used to detect the absorbance values of the prepared known 
concentrations of DOX. The plotted concentrations have been as following; 1 µg/mL, 10 µg/mL, 
30 µg/mL, 50 µg/mL, 70 µg/mL and 90 µg/mL.  The linear pattern of the graph has been translated 
into a fitting regression equation as shown in Figure (3.3) and Eq 3.2.  
 
Y= 8.05 X – 0.0245                ……. Eq. (3.2) 
 
 
Figure 3.7: standard calibration curve of DOX in PBS 
 
 
 
3.3.2. DOX Loading Capacity (LC%) and Encapsulation Efficiency (EE%): 
 
On the other hand, the resulted DOX loaded PEGylated CSNP have been analyzed with DLS in 
order for detecting the modification effect of DOX entrapment on the size, PDI and zeta potential 
values of the nanoparticles. Table (3.4) shows the results of all prepared formulations. The sizes 
of the resulted formulations have been slightly smaller than the PEGylated CSNP. Besides, the 
surface net charge values have been slightly lower also. Based on this two information, this slight 
change in size and surface charge may be attributed to the entrapped amount of DOX (97).  
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Table 3.4: DLS analysis of DOX loaded and unloaded CSNP 
 
Nano-formulation Size PDI Zeta Pot. 
CSNP  195.4 ± 3.8 0.22 ± 0.005 + 42.5 mV± 1.3 
CSNP - PEG 188.6 ± 0.5 0.19 ± 0.002 + 38.4 mV± 3.8 
CSNP- PEG - DOX 1.25 µg/ml 
mg  
177.8 ± 2.6 0.18 ± 0.002 + 35 mV ± 1.6 
CSNP-PEG - DOX 2.45 µg/ml  180.6 ± 4.3 0.20 ± 0.008 + 33.4 mV ± 0.9 
CSNP-PEG – DOX 5 µg/ml 178.5 ± 4.7 0.21 ± 0.006 + 34.6 mV ± 2.6 
CSNP-PEG – DOX 10 µg/ml  176 ± 5.7 0.22 ± 0.005 + 33.6 mV± 3.59  
 
The LC% and EE% are two main important parameters that define the efficacy of the entire drug 
delivery nano-carrier system. The results are given in averages of triplicate experimented values. 
As showed in Table (3.5), the LC% and EE% are independent from each other. They continued to 
increase gradually with increasing the fed DOX concentration, till certain concentration (10 µg/ml) 
then decreased. At this point the internal chitosan network has been saturated with DOX, besides, 
the drug has reached its saturation solubility (102). Therefore, higher drug concentrations are 
expected to be eluted in the loading supernatant media (196).  
 
Table 3.5: Resulted LC% and EE% of different DOX-PEGylated CSNP at different drug concentrations 
 
 
Drug formula LC% EE% 
1.25 µg/ml 0. 033 % 71.44 % 
2.45 µg/ml 0.08 %  77.5 % 
5 µg/ml 0.114 % 80.4 % 
10 µg/ml  0. 09 %  78.5 % 
 
The potentials of PEGylated CSNP to load such DOX concentrations are proposed to be dependent 
on its internal spacing structure besides capillary forces (197). When the initial fed DOX, 
concentrations have been compared to the calculated loaded amounts, 5 Ug/ml concentration has 
been selected as the highest LC% and EE%, for the following experiments (101, 198). 
Furthermore, the cell viability tests have confirmed the lowest viable rate of breast tumor cells 
(MCF-7) with 24 hours incubation after ingestion of 5 µg/ml nano-drug formulation using 96 well 
plate. This will be discussed in more details in cell cytotoxicity part. The selected sample of DOX 
conjugated to CSNP has been confirmed with spherical morphology through TEM images as 
shown in Figure (3.8).   
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Figure 3.8: TEM images of DOX loaded PEGylated CSNP (A, B), and schematic diagram of DOX loaded 
PEGylated CSNP 
 
 
3.3.3. UV-VIS spectrum of DOX loaded PEGylated CSNP: 
 
In order to confirm the efficiency of the prepared nano-system to effectively encapsulate DOX, 
the UV-Vis spectra of free DOX, unloaded CSNP and DOX loaded PEGylated CSNP are shown 
in Figure (3.9). The nano particulate samples have been incubated in slightly acidic pH media for 
24 hours in the ambient conditions before centrifuging. Then, the resultant supernatant has been 
matched to the UV spectrum of free DOX which has a characteristic absorption peak at wavelength 
of (481 nm) (199). The unloaded CSNP have revealed a broad absorption band at the area of 200-
300 nm. This band is thought to be related to C=O group.  
63 nm 
DOX 
C 
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Figure 3.9: UV-Vis spectra of DOX loaded CSNP, non-loaded CSNP and free DOX 
 
While the supernatant of DOX loaded PEGylated CSNP showed stronger peak on the spectrum 
with a characteristic peak at 480 nm wavelength, which is thought to be related to DOX. In fact, 
CSNP has a characteristic swelling behavior that can be generally noted in acidic pH media. That’s 
because the amino group related pKa value of chitosan is around 6.5. Therefore, the crosslinked 
framework of CSNP start degrading in this acidic pH. The protonated NH2 groups of CSNP in 
acidic pH enhances its solubility. This can improve the release of the entrapped DOX (200).   
 
3.3.4. FTIR Spectroscopy analysis:  
 
FTIR spectroscopy tests of CS powder, CSNP, DOX, PEGylated CSNP and DOX loaded 
PEGylated CSNP are shown in Figure (3.10). In chitosan powder, broad and strong peak at 3446 
cm-1 might be related to O-H stretching mode. This peak has been shifted to lower wavenumber at 
3422.3 cm-1 and 3411 cm-1 in CSNP and PEGylated CSNP respectively. This probably means that 
the more polymeric cross linkage with TPP and PEG, the lower peak shifting wavenumber. This 
refer to the enhancement of H-bonding in the two nano formulations (201). Therefore, the bonds 
in PEGylated CSNP is stronger than those in CSNP (96).  
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Figure 3.10: FTIR spectrum of CS powder, CSNP, DOX, Pegylated CSNP and DOX loaded PEGylated CSNP  
 
The peak at 1600 cm-1 in chitosan represents bending vibration amide I bond N-H. In CSNP, it has 
been shifted to 1540 cm-1. Likewise, the peak at 1650 cm-1 amide II stretching in chitosan powder 
has been shifted to 1612 cm-1 in nanoparticulate systems. This supports the assumption of 
successful TPP crosslinking of CSNP (202). Amide III bond peak of N-O has appeared in 
PEGylated CSNP at 1380 cm-1 region. (131). Furthermore, a characteristic P=O peak has been 
observed at 1155 cm-1 region of the formulated nanoparticulate systems, this peak can be related 
to the linkage between NH2 of chitosan and phosphoric of TPP.   
 
A peak at 2888.3 cm-1 wavenumber has appeared in PEGylated CSNP can be attributed to -CH2 
stretching vibration. This may enhance the assumption of successful PEGylation of CSNP (204). 
Another PEGylation specific peak is vibrational C-O-C peak that appeared with high intensity at 
1101 cm-1 (205). After introduction of DOX to the system, two characteristic peaks at 1590 cm-1 
and 1651 cm-1 have appeared in the IR spectrum compared to the spectrum of free DOX. These 
two peaks are assumed to be related to stretching C=C of DOX inside the PEGylated CSNP matrix. 
Moreover, OH stretching band has been shifted to 3430 cm-1 with more intensity and broader 
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appearance, which may represent increased strength of its hydrogen bonding $. Another peak at 
1021.3 in PEGylated DOX loaded CSNP may refer to C—O (25).  
 
3.3.5. Swelling Studies of DOX loaded PEGylated CSNP 
After 24 hours of incubation, the samples have been weighed and their swelling indices have been 
determined in two different pH media; 6.6 and 7.4. DOX loaded PEGylated CSNP have had higher 
tendency for swelling at acidic 6.5 pH media than slightly neutral 7.4 pH. Swelling indices at 6.6 
pH and 7.4 pH were 62.5 % and 7.89 % respectively. The difference in swelling behavior has been 
investigated, also, with a TEM image as shown in Figure (3.11). The nanoparticles in 7.4 pH could 
maintain their polymeric spherical shapes as referred by the blue arrows. While in 6.6 pH, the 
polymeric matrix of the nanoparticles has been destroyed (206).  
 
 
 
Figure 3.11: TEM images of DOX loaded PEGylated CSNP at pH 7.4 (a), pH 6.5 (b) after 24 hrs incubation and 
schematic illustration of the difference between non-swelled (pH7.4) and swelled nanoparticles (pH 6.6) (c)  
(c) 
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There is relationship between having high swelling rate and release of the entrapped drug from 
CSNP, which may be due to the pores formed in the matrix network of the nanosystems. Swelling 
has been shown to be affected by some parameters such temperature, swelling time, crosslinking 
degree and pH. By maintaining all these parameters fixed and changing the pH of the media, the 
effect of pH has been demonstrated. This variation between pH 6.6 and pH 7.4 may be related to 
the hydrophilicity of CSNP and its polymeric chains. The presence of some active groups such as 
—COOH, —OH and NH2 — may have another contribution (206).  
 
Besides, the protonation of chitosan (pKa 6.6) at lower pH levels is increasing and its positive 
amino groups induce its swelling. While at higher pH levels, chitosan is less protonated and 
uncharged, thus its swelling and solubility decrease (207). Another rationale is that, in higher pH 
levels, water tend to form a hydrogen bonds with functional active groups such as —COOH, —
OH and NH2 —groups. These H-bonds tend to fill the spaces inside the nano matrix and, hence, 
minimize swelling. Furthermore, the rheological behavior of DOX loaded CSNP and sizes of 
counter anions at these pH levels are participating in this swelling behavior (208). In conclusion, 
DOX loaded CSNP demonstrates a pH dependent swelling, and this has a direct effect on the 
release of the entrapped drug.   
 
3.3.6. In-vitro Release Profile:   
 
 
Figure 3.12: DOX release profile of PEGylated DOX loaded CSNP at pH 6.6 and pH 7.4 
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The in-vitro release behavior in our study has exhibited a selective pH dependent DOX release 
rate. This has been investigated with two aforementioned pH levels; 7.4 and 6.6, that mimic the 
physiological and cancerous conditions at 37°C as shown in Figure (3.12). The retention of DOX 
inside PEGylated CSNP should be equilibrated between its stability in normal noncancerous 
environment versus its targeted release at cancerous acidic conditions (209). In nanosystems, the 
release profile can be demonstrated in three main phases; desorption, swelling then erosion as 
shown in Figure (3.13). The In-vitro release behavior of DOX loaded nano-system in acidic 6.6 
pH has showed basic burst release that has been followed by controlled release of DOX. The burst 
release has been related to the diffusion of DOX out of the nano matrices. This is known as burst 
effect that entails a combination of polymeric CSNP degradation and drug desorption (210).  
 
 
 
Figure 3.13: Illustrative diagram of DOX release mechanism  
 
The burst release of DOX has been identified during the first 3 hours with around 45% at pH 6.6 
as shown in Figure (3.12). While less than 14% of the drug has been released at the pH 7.4. This 
can be a good predicting indication of the polymeric stability in normal blood pH compared to 
acidic tumor environment. This can be related to the pH media in a way that the protonation of the 
amino NH2 groups of both CS and DOX is increasing in acidic media compared to neutral one. 
Such protonation can be a main causative factor for the polymeric diffusion and erosion as we 
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mentioned before. After 3 hours of burst drug release, the drug has exhibited a slow sustained 
release over 72 hours incubation time. This controlled release may be related to simultaneous 
occurrence of minute molecules diffusion and the degradation of the remaining polymeric 
structures (97). Our results suggest that DOX release is affected with pH level of the ingestion 
media. The drug release rate has decreased by increasing  the processing pH of the media. The 
breast tumor environment is acidic because of the high anerobic glycolysis that enhance the acidity 
levels. Besides, the endocytosis uptake pathway of DOX loaded PEGylated CSNP is expected at 
such slightly acidic pH levels; however, it has been reported that its release decreases with 
extremely acidic conditions (211). The massive oxidative stress at the tumor area enhances such 
extreme acidity. Therefore, it is assumed that the tumor pH is a preferable media for the 
nanoparticles to release the entrapped DOX compared to normal physiological conditions.  
 
3.3.7. In-vitro release kinetics: 
 
The releasing kinetics of DOX loaded PEGylated CSNP have been demonstrated in order to 
predict physiological performance of the released drug. The relationship between the drug 
concentration and release rate has been described with different mathematical models; Zero-order, 
First order, Hixson crowell, Higuchi and Korsemeyer Peppas (212). According to the results, DOX 
release may fit with Higuch model at the acidic 6.6 pH. This system hypothesized that DOX 
particles are smaller than the nano-system thickness Additionally, this model entails that the 
release rate is related to the pH and the nano carrier matrix has a good solubility rate. On the other 
side, at pH 7.4, the release rate follows Korsemeyer Peppas model that assume one dimensional 
drug release relative to the drug dosage form (213).  
 
 
Table 3.6: Release kinetics of the released DOX according to different systems equations  
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3.4. Functionalization of Monoclonal Antibodies: 
 
 
 
Figure 3.14: Schematic illustration of the final mAb functionalized DOX loaded PEGylated CSNP 
 
The attachment of mAb to the surface of DOX loaded PEGylated CSNP has been suggested for 
enhancing the intracellular uptake and endocytosis. This may be achieved through specific surface 
receptors attachment of mAb to cancer cells. The functionalization of Anti-HER2 (Anti Human 
Epidermal Growth Factor II) mAb and Anti-hMAM (Anti Human Mammaglobin) mAb to the 
surfaces of the nanoparticles has slightly increased their sizes as shown by the TEM images in 
Figure (3.14) and (3.15).  
 
Each mAb has been immobilized to the surface of the nanoparticles separately by EDC 
crosslinking. Supported activation of COOH terminal groups on the PEGylated surfaces of DOX 
loaded CSNP has prepared the surface of these nanoparticles for further attachments of the mAbs. 
In other words, this may facilitate the entry of mAb for successful surface conjugation. Therefore, 
ratio between EDC to the mAbs was 5:1. This may increase the opportunities of surface satisfaction 
of the nanoparticles with the antibodies separately. This could be confirmed with FTIR spectrum. 
Furthermore, the size of the nanoparticles is greater than the mAbs, therefore the ratio of 
nanoparticles to the mAbs was high (214).  
 
The presence of PEG layer besides a stronger EDC supported linkage, may together help the 
nanocarriers to proceed their way without detachment of the surface mAbs (146). This is from a 
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biological point of view. Furthermore, high consideration has been given to the use of PBS for 
frequent washing in order to eliminate the presence of the unfavorable attached EDC molecules. 
This may grasp further circulating molecules (216).  
 
 
Figure 3.15: TEM images of Anti-hMAM DOX loaded PEGylated CSNP (A, B) and Anti-HER2 DOX loaded 
PEGylated CSNP (C, D) 
 
In order to explore the surface chemistry of the particles surfaces that are functionalized with 
mAbs, HNMR spectrum has been conducted as shown in Figure (3.16). Peaks at 2.4, 2.6 and 2.7 
ppm are responding of H protons of CH2 groups of mAb functionalized nanoparticles. Besides, the 
appearance of triplicate peaks at 3.2 and 3.3 ppm are representing amino NH2 groups, which may 
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confirm the conjugation of the antibodies to the PEGylated surface. The increased amount of 
nitrogen within the surface of nanoparticles can be illustrated with the increased immobilization 
of the mAbs. Moreover, FTIR spectrum has been conducted as well, and it confirm this assumption 
of surface coverage with mAbs related NH2 groups (217).  
 
 
 
 
Figure 3.16: HNMR spectrum of Anti-hMAM / DOX loaded PEGylated CSNP (A) and Anti-HER2 / DOX loaded 
PEGylated CSNP (B) 
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The FTIR spectrum of Anti-HER2 DOX loaded PEGylated CSNP and Anti-hMAM DOX loaded 
PEGylated CSNP has been explored to define the change in the absorption peaks relative the non-
functionalized DOX loaded PEGylated CSNP. This is shown in Figure (3.17). The shifting of OH 
peak from 3430 cm-1 to 3300 is an indication of the pronounced COOH group to the surface of the 
CSNP. Moreover, the increased intensity of the peak at 1600 cm-1 can be attributed to the increased 
surface coverage with NH2 groups. These groups may be related to the immobilized mAbs (216). 
The disappearance of the characteristic peak of PEG at 1094 cm-1 indicates, also, the conjugation 
of the mAbs to the surfaces.  
 
Figure 3.17: FTIR spectrum of mAbs /DOX loaded PEGylated CSNP and non-functionalized DOX loaded 
PEGylated CSNPs 
 
3.5. Cytotoxicity Analysis: 
 
 The cytotoxic effect of different nano-formulated systems on MCF7 cells have been more 
prominent than various free DOX drug concentrations. L929 cells were less responsive to the 
different nano-formulations as shown in Figure (3.18) (102).  
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Figure 3.18: Colorimetric MTT assay of DOX loaded PEGylated CSNP (1.25, 2.5, 5 and 10 Ug/ml) (A), Free DOX 
concentrations (1.25, 2.5, 5 and 1 Ug/ml) (B) and Anti-HER2 and Anti-hMAM functionalized DOX loaded 
PEGylated CSNP. 
 
 
 
A 
B 
C 
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Various nano-formulations have been screened including unloaded CSNP, PEGylated CSNP, 
DOX loaded PEGylated CSNP (variable concentrations), free DOX, Anti-HER2 functionalized 
PEGylated DOX loaded CSNP and Anti hMAM functionalized PEGylated DOX loaded CSNP. 
The cytotoxicity results suggest that nanoformulated DOX systems have shown greater toxicity on 
cancerous MCF7 cells. As shown in Figure (3.14A), PEGylated DOX loaded CSNP with drug 
concentrations of 1.25, 2.5, 5 and 10 µg/ml could achieve MCF7 cell viability rates of 24.7± 4.2 
%, 18.66 ±2.3%, 14.98± 1.5% and 39.44± 3.1% respectively. Normal L929 cells have been less 
affected by these nano-formulated drug concentrations and less responsive to the released drug, 
although both types of cells had identical same incubation conditions of time, type of media and 
drug interval concentrations. The released drug could achieve successful endocytosis in case of 
MCF7 and killed more than 50% of the seeded cells. (130). 
 
The nanoparticles encapsulating 5 µg/ml DOX has shown the highest cytotoxicity effect with 
14.89% viable MCF7 cells. Le et al. has reported the minimal cytotoxic effect of the released DOX 
when the drug concentration is increasing than proposed concentrations in this study (218). On the 
other hand, the effect of the same 5Ug/ml nano-DOX formula on normal L929 has been the least 
compared with other concentrations. This may put some confirmatory assets on its therapeutic 
durability and biological safety (102).  
 
Free DOX concentrations have demonstrated higher viability rates of MCF7 cells with 30 ± 1.98%, 
34 ± 1.45%, 38 ± 4.31% and 45 ± 2.21% viability rates for similar free drug concentrations of the 
nano formulated DOX. Therefore, their cytotoxic effect on cancerous cells is lower than nano 
DOX formulations. We have demonstrated their partial dose dependent cytotoxicity on MCF7 and 
L929. The most efficient free DOX concentration could revel around 30 ± 1.98 % viability rate. 
While in nano formulated DOX, the lowest viability rate has been 14.89 ± 1.5%. This suggests a 
good indication that our PEGylated CSNP system has improved the cellular uptake and 
intracellular delivery of DOX with one-time higher rate, under the same exposure time relative to 
free DOX (53). Confirmatory bright filed images of MCF7 and L929 after exposure to different 
drug formulations are shown in Figures (3.19) -(3.22).    
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Figure 3.19: Bright field images of L929 cells with white arrows referring to living cells (A), and MCF7 cells with 
white arrows referring to dead cells (B) after exposure to DOX – PEGylated CSNP (0.5 µg/ml) 
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Figure 3.20: Bright field images of L929 cells with white arrows referring to dead cells (A), and MCF7 cells with 
white arrows referring to living cells (B), after exposure to Free DOX  
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Figure 3.21: Bright field images of L929 cell line with white arrows referring to living cells (A), and MCF7 cell line 
with white arrows referring to dead cells (B) cells after exposure to Anti-HER2 functionalized DOX loaded 
PEGylated CSNP 
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Figure 3.22: Bright field images of L929 cells with white arrows referring to living cells (A) and MCF7 with white 
arrows referring to dead cells (B) cells after exposure to Anti-hMAM functionalized DOX loaded PEGylated CSNP 
 
 
 
 101 
 
Functionalization of monoclonal antibodies to the surfaces of DOX loaded PEGylated CSNP as a 
targeting moiety was assumed to be a productive therapeutic conjugate in terms of cancer cell 
cytotoxicity. This has empowered the cellular uptake and cell viability rates of these nano 
formulations. In this sense, Anti HER2 and Anti hMAM antibodies have been used for 
functionalization of DOX loaded PEGylated CSNP separately. This could enhance the tumor cell 
susceptibility and higher intracellular accumulation of the released DOX. Our results have showed 
the potential of the nano formulated DOX functionalized with these monoclonal antibodies to 
increase its cytotoxic effect in MCF7 three times as free DOX, while maintaining higher viability 
rates of normal L929 cells (131).  
 
Anti-HER2 and Anti-hMAM functionalized nano formulations have shown MCF7 viability rates 
of 1.79 ± 0.06% and 2.99 ± 0.023% respectively. While Normal L929 have been less responsive 
and less affected by the same formulations. This may be a good marking point that MCF7 are more 
affected by these antibodies functionalized nano formulations, while normal L929 cells are less 
susceptible and less affected. Specific antigen-antibody mediated drug accumulation my 
developed more efficient cellular endocytosis and, hence, higher drug efficacy on MCF7. On the 
other hand, L929 normal cells lack such tumor cell specific receptors like HER2, for instance. 
Therefore, such intracellular drug uptake is not expected, and receptor mediated coupling 
mechanism hiders drug release or accumulation with normal cells (219). The bright field images 
of the cells after identical exposure to antibodies functionalized DOX loaded PEGylated CSNP 
have demonstrated the viability profile. The difference in cellular shape and uniformity responses 
of both types of cells may exhibit their different susceptibilities. 
 
The MTT test has been performed in CO2 incubator under processing temperature of 37 °C. The 
temperature has been proposed to affect the intracellular action of DOX and affect its diffusion. In 
this sense, Miller’s law of diffusion entails a strong relationship between the temperature and drug 
diffusion rates (220). Therefore, the diffusion and cytotoxicity profiles of all our experimented 
formulations, including loaded and unloaded DOX, are less likely to be affected by this 
relationship. That’s because the experimental processing temperature was 37°C, which is higher 
than the intermolecular self-aggregation temperature of DOX. In this temperature, intermolecular 
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π – interaction may be formulated specially less than 4°C, which minimize the diffusion of DOX. 
However, our study has been performed at physiological 37°C temperature (221).  
 
3.6. Size increment profile:  
 
Over the different activities of our study, variable sizes of CSNP have been obtained. The size 
increment over all the activities didn’t exceed 10%. This is a good indication for the surface 
stability. The size increment after PEGylation of CSNP, encapsulation of DOX to PEGylated 
CSNP, functionalization of Anti-HER2 to DOX loaded PEGylated CSNP and Functionalization 
of Anti-hMAM to DOX loaded PEGylated CSNP have been 10%, 7.23%, 4.3% and 4.72% (222). 
 
    
 
 
 
 
Figure 3.23: TEM images and the relevant DLS histograms of non-PEGylated CSNP (A, B) and 
PEGylated CSNP (C, D) 
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Figure 3.24: TEM images and their relevant DLS histograms of DOX loaded PEGylated CSNP (E, F), Anti-
HER2 DOX loaded PEGylated CSNP (G, H), and Anti-hMAM DOX loaded PEGylated CSNP (I, J)   
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Supporting Information: 
 
SI. 1. Synthesis of chitosan nanoparticles.  
 
SI. 1.1. Dissolving Chitosan: 
 
Chitosan acidic solution has been prepared simply through dissolving LMW chitosan powder with 
different weights including 1 gm, 0.5 gm, 0.25 gm and 0.05 gm in 1% acetic acid. The pH has 
been adjusted to 5.0 using 0.1N NaOH. These prepared solutions have been left to be mixed and 
dissolve for 24 hours under magnetic stirring at 750 RPM within the ambient temperature. The 
resulted four solutions have showed different viscosities and some dissolved traces have been 
removed out using 0.4 Um syringe filter mesh. All preparation parameters and conditions have 
been controlled within this step-in order to obtain homogenous chitosan acidic solutions. The 
stirring beakers have been covered with protective par-film sheets in order for avoiding the 
entrance of any contaminants, and suitable sizes of magnetic bars have been used for the mixing 
process.  
SI. 1.2. Dissolving Sodium tri-polyphosphate:    
 
Sodium tri-polyphosphate is a chemical cross linker that has been used in this work in order to 
induce the ionic gelation process through which, chitosan nanoparticles would be formulated.  TPP 
has been dissolved in purified distilled water within four different concentrations; 0.1%, 0.4%, 
0.5% and 0.7%. Suitable sizes of magnetic bars have been used for stirring process. The solutions 
have been rapidly mixed within 35 minutes at 500 RPM within the ambient conditions.    
 
 SI. 1.3. Preparation of Crosslinked chitosan nanoparticles: 
 
After formation of homogenous chitosan and TPP solutions, they have been mixed together. 
Whitish clouds of chitosan nanoparticles have been spontaneously formed upon addition of the 
two polymers together. In order for separating these nanoparticles, we have applied efficient 
centrifuging forces. Therefore, the reacted polymers part, that formulated crosslinked chitosan 
nanoparticles, could be separated from the unreacted eluted polymers. The resulted pellet of 
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chitosan nanoparticles has been used for further investigative characterization techniques. For this 
purpose, the pellet has been divided into three sections as shown in figure SI. 1 and table SI. 1.   
 
Table SI. 1: variable conditions for characterizing chitosan nanoparticles 
 
Nanoparticles pellet Action Characterization Purpose 
First part (minor)  Oven drying   Scanning electron microscopy (SEM),  
Second part (moderate) Sonication + dilution 
(distilled water) 
Dynamic light scattering (DLS), Ultraviolet-Visible 
spectrophotometry (UV-VIS) and Transmission electron 
microscopy (TEM) 
Third part (major) Freeze drying  Fourier transmission infra-red spectroscopy (FTIR), X-ray 
Diffraction (XRD)  
 
 
 
Figure SI. 1: Divided pellet undergoes further investigation techniques with a prior sample preparation technique 
such as oven drying, freeze drying and resuspending in distilled water.  
 
SI. 2. Factors affecting chitosan nanoparticles: 
 
The morphological chemical properties of chitosan nanoparticles are significantly affected with 
various parameters and factors. This is a part of the reason of why chitosan is a remarkable 
biopolymer and possess attractive advantages for various biological and non-biological 
applications. Changing some parameters such as polymers concentration, mixing rate and mixing 
time can obviously change the size and shape of the formulated nanoparticles. It has a simple 
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analogy like tailoring a specific nano-carrier or nanosystem with providing certain specific resulted 
features and properties, by playing with these stated parameters.  
 
SI. 2.1. Effect of polymers concentrations:  
 
The particle size, shape, distribution and surface charge of the prepared chitosan nanoparticles can 
be influenced by the concentrations of chitosan and TPP. In order to investigate this influence, 
various concentrations of both polymers have been applied with keeping all other preparation 
parameters constant. Identical volumes of both polymer solutions have been applied, while their 
concentrations have been varied. Four different concentrations of chitosan acidic solutions have 
been used; 0.05%, 0.25%, 0.5% and 1% (w/v).  
 
On the other hand, sodium tri-poly phosphate concentrations were 0.1%, 0.4%, 0.5% and 0.7% 
(w/v). Sixteen samples of whitish clouds of chitosan nanoparticles have been formulated up on 
drop wise addition of sodium tri-polyphosphate to chitosan acidic solutions with a dropping 
syringe. Based on the number of concentrations of both polymers, the optimization of the 
nanoparticles has taken place in a quadruple manner as shown in table 2.  
 
Table SI. 2: General scheme for the applied polymers concentrations; Cs and TPP 
 
Sample Cs (w/v) %  TPP (w/v) % 
0.05 0.1 0.5 1  0.1 0.4 0.5 0.7 
1           
2          
3          
4          
5          
6          
7          
8          
9          
10          
11          
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12          
13          
14          
15          
16          
 
The mixture of chitosan solution and TPP has been left for mixing on the magnetic stirring under 
the previously stated preparation parameters in terms of mild speed and time within protected 
ambient conditions. The resulted sixteen samples of chitosan nanoparticles have been visually 
analyzed as turbid suspensions of undissolved white clouds of nanoparticles. After using particles 
size analyzer which has been based on dynamic light scattering physical principle (Malvern 
Zetasizer®), sample 8 has been the sample of choice in terms of size and distribution.  
 
SI. 2.2. The effect of Stirring speed:    
 
Another significant factor that has a direct influence on the resulted chitosan nanoparticles is 
related to the identified mixing technique. Stirring speed has been reported to directly affect the 
NP’s size and distribution (223). Although it has reported by Oliviera et. al., that stirring time and 
speed have low influence on the size and distribution of the formulated nanoparticles (224). We 
have investigated that this contradict with our study. Four main different stirring speeds have been 
investigated and analyzed to produce various sizes and distributions; (250, 500, 750 and 1000) 
RPM. All other parameters have been constant including polymers concentrations. The sample of 
choice, sample 8, has been investigated in these four different stirring speeds as shown in table 2. 
 
Table SI. 3: Various stirring speed provide variation of Cs nanoparticle’s size and distribution. 
 
Stirring speed Particle size PDI 
250 RPM 182 ± 5.3 0.37 ± 0.004 
500 RPM  345.9 ± 1.3 0.517 ± 0.003 
750 RPM  357.2 ± 4.45 0.512 ± 0.041 
1000 RPM  391.4 ± 2.2 0.491 ± 0.007 
 
SI. 2.3. The effect of stirring time: 
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Stirring time is one of the main influential factors that affect the size and distribution uniformity 
of the formulated chitosan nanoparticles.  In order to investigate that notion, we have performed 
this preparation procedure with keeping all other preparation factors constant. The polymers 
concentrations, stirring speeds and temperature have been kept constant with changing the 
performing stirring time. The influence of changing stirring time on particle size and distribution 
has been studied with three different time slots; (15, 30 and 60) minutes as shown in figure 3. 
According to the resulted smallest particles sizes and smallest PDI, the optimized procedure has 
been selected. (225, 226) 
 
Table SI. 4: Variation of the stirring time provides variation of particles size and distribution.  
 
Stirring time  Particle size PDI  
15 min 245 ± 7.6 0.67 ± 0.004 
30 min 182.2 ± 5.45 0.304 ± 0.009 
60 min  209.3 ± 25.45 0.609 ± 0.082 
  
SI. 2.4. The effect of chitosan molecular weight:  
 
Molecular weight of raw chitosan powder is another effective factor that influence the size of the 
resulted chitosan nanoparticles (227). It has been reported by many studies that there is a direct 
relationship between the molecular weight of chitosan relative to particles size and distribution of 
the resulted chitosan nanoparticles (228). Considerably, the effect of varying the molecular 
weights of chitosan on the resulted nanoparticles has been studied with holding the initial chitosan 
and TPP constant. The molecular weights of chitosan have been changed within three different 
preparations; Low molecular weight chitosan (LMWC), medium molecular weight chitosan 
(MMWC) and high molecular weight chitosan (HMWC). However, all other preparation 
parameters and factors have been kept constant, and the optimized molecular weight has been 
selected based on the resulted particle size and distribution.  
 
  
Table SI. 5: Variation of chitosan molecular weight provides variation of particles size and distribution 
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Chitosan Molecular weight Degree of Deacetylation particles size PDI 
LMWC (110) 89.9 % 187 ± 2.7 0.282 ± 0.015 
MMWC (400) 84.8 % 357 ± 80.5 0.81 ± 0.14 
HMWC (800) 76 % 444.2 ± 106.9 0.52 ± 0.07 
 
SI. 2.5. The effect of pH:  
The external morphology mean sizes and uniform distribution of chitosan nanoparticles can be 
affected by different pH of chitosan solution. The relation between the crosslinking process of 
chitosan/TPP and changing the pH of chitosan solution has been reported by some studies (229). 
For investigating this effect, we have adjusted the pH of chitosan solution from 2.6 to 5.5 (2.6, 3.1, 
3.5, 4.5, 5 and 5.5). The protonation degree of chitosan polymer can greatly control the cross-
linking process of CSNP. On the other hand, this protonation degree can be affected with chitosan 
solution pH, therefore we need to investigate this factor and whether it needs to be controlled 
within specific range that doesn’t harm the intended physiological environment in which the 
nanoparticle would deliver certain drug or not.   
 
Table SI. 6: various processing pH provide variation of particles size and distribution 
 
pH Size PDI 
5.5 196 ± 4.1 0.42 ± 0.06 
5 182 ±3.7 0.22 ± 0.005 
4.5 180.8 ± 4.4 0.34 ± 0.003 
3.5 162 ± 4.6 0.35 ± 0.008 
3.1 147 ±1.9 0.41 ± 0.05 
2.6 136 ± 6.1 0.47 ± 0.005 
 
SI. 3. Stability of chitosan nanoparticles: 
Throughout all the optimization procedure and manipulation of the different preparation factors of 
the resulted chitosan nanoparticles, we could identify the optimum procedure through which we 
can obtain chitosan nanoparticles with satisfying physical and chemical properties. The main 
characteristic features of the nano-system that we have investigated are particle size, poly 
distribution and zeta potential value as shown in table 6. 
 111 
 
 
Table SI. 7: Stability profile for the prepared chitosan nanoparticles along over three weeks 
 
 
 
 
 
 
 
 
 
 
 
 
Zeta potential is an indicative parameter to the surface charge and hence the aggregation tendency 
or size stability in the intended suspending medium as shown in table 7 (230). This is a very 
important parameter whenever the formulated nano-system would be intended to be injected in a 
biological tissue within biomedical applications. In other words, the size stability of the in-vivo 
colloidal nanoparticles system can be assessed with zeta potential value.  
 
Table SI. 8: Various ranges of Zeta potential values with their corresponding aggregation tendencies (231) 
 
 
 
 
 
 
 
Time Particle size PDI 
1 day 183.7 ± 5.8 0.20 
2 days 187 ± 3.9 0192 
4 days 187.6 ± 4.6 0.223 
6 days 195 ± 2.12 0.253 
8 days 198.5 ± 3.5 0.262 
10 days 193.4 ± 6.1 0.292 
12 days 184.5 ± 5.7 0.239 
14 days 192.2 ± 8.4 0.209 
16 days 200.1 ± 2.1 0.190 
18 days 196 ± 3.4 0.242 
20 days 204.4 ± 4.6 0.240 
22 days 201.1 ± 5.2 0.189 
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SI. 4. Theoretical and Instrumental background:  
 
SI. 4.1. Ultrasonic Probe Sonicator (Polytron, Thermo-fisher:  
 
Ultrasonic probe sonicator is an instrument that is used for mixing and extraction of various 
chemical or polymeric compounds. This device is working by generating powerful energy in the 
form of sound waves that are enough to agitate or suspend micro and nano sized particles in a 
solution (232). These sound waves are ultrasonic waves (frequency > 20 kHz). They provide rapid 
and violent vibration of the probe tip, and this creates a kind of cavitation that collapse within the 
solution or medium as shown in (Figure 2).   
 
 
Figure SI. 2:  controlled compression and expansion energy that bring particles to larger sizes which later 
breakdown into much smaller ones (232) 
 
This cavitation intensity is controlled by the setting agitation time and amplitude settings. It creates 
what is called cavitation bubbles that grow in size until it reaches a critical size that can 
aggressively disrupt the intermolecular covalent bonding of the applied medium as shown in 
(figure 2). Therefore, the greater the frequency, the stronger the waves, the higher cavitation 
intensity and hence the stronger particles agitation. It has been recommended by many studies that 
ultrasonic probe sonicator is a recommended high-speed mixing technique and put it as the first 
technique of choice for mixing (233) 
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Ultrasonic probe sonicator is mainly composed of three main parts; generator, converter and probe 
tip (figure 3). Generator is the processing unite through which, we can control the sonication 
parameters. It provides high voltage pulses of electrical energy that is produced basically form 
normal alternating current and convert into such powerful pulses through that generator unite 
(234).  
 
 
Figure SI. 3: The three main Instrumental parts of a Probe-Sonicator (234) 
 
Converter is a piezoelectric unite of the ultrasonic instrument. It is typically controlled through the 
high voltage pulses that are created by the generator.  These pulses provide such enough powerful 
energy at a certain un-fluctuated frequency of 20 kHz. The main function of the converter is to 
convert the produced electrical energy into mechanical energy. Therefor there is a high voltage 
cable that connect between the converter and the generator. The outer shape of converter, as shown 
in figure X, is cylindrical. The third part of the ultrasonic sonicator is the probe or horn. This the 
instrumental part of the device the is put in direct contact to the applied sample. It has threaded 
ends whose longitudinal tip expands and contract during processing (235).  
 
SI. 4.2. Freeze drying (BIOBASE, Jinan, China): 
 
Freeze drying is a dehydration process or removal of solvent and it is called also lyophilization. It 
is a frequently used technique in many pharmaceutical industries, different scientific laboratories 
and food industries. Basically, freeze drying is applied for drying heat labile samples so that it 
becomes more stable in a powdered form without presence of moisture any solvent after being 
frozen (236). Samples like proteins, tissues, plasma, dead cells and pharmaceuticals are extremely 
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heat labile and can’t be dried by oven drying technique, therefore we can use freeze drying for 
keeping them in more a stable state. The basic scientific concept behind freeze drying is related to 
sublimation phenomenon. This phenomenon states that solid iced material can undergo phase 
transition to become gaseous vapor without being exposed to the liquid state. This occurs by 
applying low pressure and low temperature that allow the frozen water or solvent to sublimate as 
shown in (figure 4). This diagram, also, represents water phase diagram. In other words, it 
represents the physical state of water under different conditions including temperature and 
pressure. Through the diagrams, sublimation occurs when pressure is lowered, and heat is applied 
to the frozen sample. Sublimation rate increases more with vacuum. This is a simple explanation 
of the freeze-drying process and its scientific concept.  
 
Figure SI. 4: Theoretical illustration of freeze-drying (237) 
 
Sublimation is the main target for a freeze drier unite in order to completely dry the sample and 
evaporate the remaining excess water by breaking the bonds between the sample and water. Three 
main phases for the freeze drier to pass through as shown in (figure 5); freezing, primary drying 
(vacuum sublimation) and secondary drying (adsorption) (238). 
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Figure SI. 5: Graphical illustration for different stages of freeze-drying process (238) 
 
SI. 4.2.1. Freezing: 
In this phase, the sample is completely frozen in a vial that is done by freezer or even a chilled 
bath. The sample is cooled down to reach below the triple point in order to ensure that the sample 
will not undergo melting but rater with expose to sublimation.  
 
SI. 4.2.2. Primary drying (vacuum sublimation): 
This is the stage in which around 95% of the entire drying process takes place. The application of 
vacuum in this stage is a reason of rapid sublimation. It is a slow phase in which preassure is 
lowerd and moderate heat is applied because excessive heat may cause breakdown or change in 
the structure of the sample. The released water vapor is condensed and solidified within the 
condenser.  
SI. 4.2.3. secondary drying:  
It is called, also, adsorption phase in which the ionic bonds between water and the applied material 
is broken and removed. This breakage is owing to the increased temperature in the freeze drier to 
a degree higher than the primary drying phase so that the remaining 1-5 % of the residual moisture 
is removed. The dried samples can be preserved within dry un-moisturized environment such as 
silica jar or refrigerator so that they can be prepared for later phases of the study.  
 
The main purpose of using freeze drier during the current study has been to provide a stable form 
of free unloaded CSNP, PEGylated CSNP and DOX loaded CSNP. The dried forms of these 
nanoparticles have been used for further characterization analytical techniques such as FTIR and 
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XRD. Additionally, these dried forms have had more stability profile and longer shelf life as a 
powered form. They can be used anytime with a definite amount of micro and milligrams of the 
nanoparticles. During drug loading and release studies, we have used to weigh certain amppunts 
of nanoparticles in order to investigate some critical analytical tests such as release, loading and 
cell viability percentages.  
 
SI. 4.3. Magnetic stirrer (ISG®, China)  
 
It is a laboratory device that is frequently used in most chemistry, physic and biology laboratories 
for mixing of different fluids. It is a simple device in which a magnetic bar is allowed to stir at the 
bottom of certain sample as shown in figure 6 This rotating bar is stirring within a rotating 
magnetic field. The sited bar is immersed inside the vessel of liquid sample, and it must be of 
suitable size relative to the applied vessel. 
 
Figure 6: Magnetic stirrers (239) 
 
 In case of glass vessel, it can be broken if the size of the stirring bar is quite large and strong. 
Another important factor that affect the stirring process is the viscosity of the liquid. When the 
applied liquid has high volum or high viscosity, additional mechanical stirring is required. The 
main controllers with magnetic stirrer device are rotating speed, that is defined as round per minute 
(RPM), time that is defined in minutes and temperature, that is defined by Celsius C (240). The 
size of the stirring bar is another considerable factor that variably affect mixing process. As shown 
in figure 7, there is a variety of sizes and shapes of the used magnetic bars. The selection of a 
specific size or shape is basically related to the purpose of mixing process and the size of the 
container in which we perform mixing of the sample.  
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Figure 7: Different shapes of magnetic mixing bars (241)  
 
 
 
SI. 4.4. Centrifugator (HERMLE Labotechnik 36 HK, Germany) 
 
Centrifugation is one of the fast separation techniques that involves sedimentation of suspended 
particles to the base of a liquid medium. This sedimentation can take place naturally without any 
external interference, but this may take very long time. Many factors affect the particles 
sedimentation or separation including particles shape, density and size, in addition to the viscosity 
and temperature of the suspending medium. it has wide application in most biological and chemical 
experiments such as DNA separation and proteins purification (242). 
 
It is a simple instrument in which the sample is placed in a vessel called centrifuging tube. This 
tube is allowed to rotate in a rotor whose speed is adjusted before the sedimentation process. As 
the rotor speed gets higher, a centrifugal force is moved and each particle in the medium will sense 
that force as shown in (figure 8). This result in immediate sedimentation of these particles. The 
sedimentation rate is directly proportional to the difference between the density of the medium and 
the density of its suspended particles. Additionally, the viscosity and some other physical and 
chemical properties influence the sedimentation rate. If we fixed the viscosity of the medium and 
centrifugal forces, the molecular weight of the dissolved particles will be directly proportional to 
the sedimentation rate (243). 
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Figure 8: Illustrative description of centrifuging process  (244) 
 
 
SI. 4.5. Oven drying (TITANOX, Italy):  
 
Drying by oven is the process of removing any solvent that is mixed with the applied sample, and 
this sample must be non-heat labile in order to avoid its destruction. It is applicable in small scales 
like laboratories and larger industrial scale as well. The main purpose of oven drying remains the 
same at both scales is to remove the mixed solvent and avoiding moisture. It is completely made 
of stainless steel and have a key and lock door as shown in (figure 9). During our experiment, 
drying oven has been used to dry PEGylated and non-PEGylated chitosan nanoparticles so as to 
be ready for SEM analysis. Each sample has been spreaded over an aluminum foil that has been 
fixed on a simple watch glass, then entered to the oven that has been adjusted at 60C for 10 
minutes in order to evaporate the solvent. In few times, the drying oven has been used to sterilize 
and dry the applicable used glassware.  (245)  
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Figure 5.5: Microscopic images  
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Conclusion: 
 
The current study has developed a therapeutic assumption of developing a selective targeted drug 
delivery system for the treatment of breast cancer. The proposed system has intended chitosan 
nanoparticles in order to entrap DOX inside, with maintaining the external surface of the 
nanoparticles decorated with PEG polymer. In order to enhance its specificity and sensitivity, the 
nano-system has been functionalized with two different types of breast cancer specific monoclonal 
antibodies; Anti-HER2 and Anti-hMAM. Along over the study, some characterization techniques 
have been applied as confirmatory procedure to ensure the durability of the final therapeutic cargo. 
Examples of which, DLS, TEM, XRD, FTIR, UV-VIS and HNMR. In this sense, primary size 
adjustment of blank unloaded CSNP has been performed to put some control over the size, surface 
charges and stability in different pH media. Then PEG has been grafted on the external surface of 
CSNP in order to enhance its stability against immunogenic responses and prevent its lymphatic 
uptake or RES uptake. Three PEG concentrations have been demonstrated; 5% PEG had higher 
stability compared with other proposed concentrations with the lowest particle size. This is because 
the final size of the nano-system has been supposed to be less than 200 nm. That is because the 
RES capturing size limit is known to be hindered for size range less than 200nm.  After confirming 
stability of the PEGylated CSNP and its size stability below that RES opsonization range, DOX 
has been encapsulated in different concentrations with various nano-formulations. 5Ug/ml 
concentration formula has been the most effective one in terms of loading capacity and surface 
stability. Therefore, it has been selected for the functionalization of mAbs. Each one of the mAbs 
has been functionalized separately; having two final types of nano-functionalized formulations. 
The cytotoxicity analysis has been conducted against MCF7 breast cancer cells and L929 
fibroblasts has been conducted. Various nano-formulations have been tested against the effect of 
free DOX on the same two types of cells with maintaining fixed temperature, drug concentration 
and incubation period. The Anti-HER2 and Anti-hMAM functionalization could promote the 
MCF7 cytotoxicity, with achieving less than 3% cell viability. While, L929 cells were less reactive 
and less responsive than MCF7. Therefore, the assumption of encapsulating DOX into a selective 
targeted nano-system has enhanced its in-vitro therapeutic effect with promoted cancer cell 
endocytosis. Bright filed images have exhibited cancerous and normal cell responses to the 
developed formulations. Therefore, the current study recommend the application of polymeric 
PEGylated chitosan nanocarrier with mAbs functionalization as a novel therapeutic system for 
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selective release of the entrapped DOX. This may provide one of the nanoscience based biomedical 
solutions for breast cancer treatment.   
 
Future Perspectives:  
 
During this study, some tests and experiments were required to be implemented in order to give a 
clear understanding of the structural and therapeutic efficiency of the developed nano-
formulations. The structural stability of the developed nano-formulations can be empowered with 
the following:  
 
o Body fluid analysis me give a better prediction of the biological behavior of the developed 
formulation. This will detect the efficacy of some parameters that have been already tested 
in this study. Particles stability along over the its site of introduction till reaching its site of 
action can be demonstrated with this test. Besides, the convenience of the nanoparticles’ 
sizes developed in this study can be confirmed with this test.  
 
o Animal testing may improve the pharmacokinetic and pharmacodynamic profiles of the 
developed nano-formulations. Detecting some parameters such as plasma level and 
elimination rate of the injected drug may promote a better understanding about the assigned 
dose of the final drug. Besides, monitoring In-vivo blood release of the drug can be another 
confirmatory procedure that is achieved with such animal testing. It illustrates a clear 
relationship between the release rate and different pH leves.   
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